


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:49:33Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405195" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405195</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>jdst</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Diabetes Sci Technol</journal-id><journal-id journal-id-type="iso-abbrev">J Diabetes Sci Technol</journal-id><journal-id journal-id-type="pmc-domain-id">967</journal-id><journal-id journal-id-type="pmc-domain">jdst</journal-id><journal-id journal-id-type="publisher-id">DST</journal-id><journal-title-group><journal-title>Journal of Diabetes Science and Technology</journal-title></journal-title-group><issn pub-type="epub">1932-2968</issn><publisher><publisher-name>Diabetes Technology Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405195</article-id><article-id pub-id-type="pmcid-ver">PMC12405195.1</article-id><article-id pub-id-type="pmcaid">12405195</article-id><article-id pub-id-type="pmcaiid">12405195</article-id><article-id pub-id-type="pmid">40891490</article-id><article-id pub-id-type="doi">10.1177/19322968251353811</article-id><article-id pub-id-type="publisher-id">10.1177_19322968251353811</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Scoping Review&#8212;Diabetes Technology for Individuals on Kidney Replacement Therapy (Dialysis): Current Trends and Future Directions</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8141-1423</contrib-id><name name-style="western"><surname>Habte-Asres</surname><given-names initials="HH">Hellena Hailu</given-names></name><degrees>PhD</degrees><xref rid="aff1-19322968251353811" ref-type="aff">1</xref><xref rid="aff2-19322968251353811" ref-type="aff">2</xref><xref rid="corresp1-19322968251353811" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Suglo</surname><given-names initials="JN">Joseph Ngmenesegre</given-names></name><degrees>PhD</degrees><xref rid="aff1-19322968251353811" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chaudhry</surname><given-names initials="K">Khuram</given-names></name><degrees>MD</degrees><xref rid="aff3-19322968251353811" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Forbes</surname><given-names initials="A">Angus</given-names></name><degrees>PhD</degrees><xref rid="aff1-19322968251353811" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wheeler</surname><given-names initials="DC">David C.</given-names></name><degrees>MD</degrees><xref rid="aff4-19322968251353811" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Karalliedde</surname><given-names initials="J">Janaka</given-names></name><degrees>MD, PhD</degrees><xref rid="aff3-19322968251353811" ref-type="aff">3</xref><xref rid="aff5-19322968251353811" ref-type="aff">5</xref></contrib></contrib-group><aff id="aff1-19322968251353811"><label>1</label>Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King&#8217;s College London, London, UK</aff><aff id="aff2-19322968251353811"><label>2</label>St Pancras Kidney Diabetes and Eye Centre, Royal Free London NHS Foundation Trust, London, UK</aff><aff id="aff3-19322968251353811"><label>3</label>Guy&#8217;s and St Thomas NHS Foundation Trust, Guy&#8217;s Hospital, London, UK</aff><aff id="aff4-19322968251353811"><label>4</label>UCL Department of Nephrology, University College London, London, UK</aff><aff id="aff5-19322968251353811"><label>5</label>School of Cardiovascular Medicine and Sciences, King&#8217;s College London, London, UK</aff><author-notes><corresp id="corresp1-19322968251353811">Hellena Hailu Habte-Asres, PhD, Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King&#8217;s College London, Room 4.26 James Clerk Maxwell Building, 57 Waterloo Road, London SE1 8WA, UK. Email: <email>hellena.habete-asres@kcl.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><issue-id pub-id-type="pmc-issue-id">475270</issue-id><elocation-id>19322968251353811</elocation-id><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Diabetes Technology Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="society">Diabetes Technology Society</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="10.1177_19322968251353811.pdf"/><abstract><sec id="section1-19322968251353811"><title>Aim:</title><p>This review aims to map the existing literature on the use of diabetes technology in people receiving dialysis, with a focus on utilization, accuracy, and effectiveness.</p></sec><sec id="section2-19322968251353811"><title>Methods:</title><p>A scoping review was conducted using the Joanna Briggs Institute methodology, with systematic searches of Medline, Embase, and CINAHL for studies on diabetes technologies in dialysis populations.</p></sec><sec id="section3-19322968251353811"><title>Results:</title><p>The search identified 1060 continuous glucose monitoring (CGM) and 1467 continuous subcutaneous insulin infusion or automated insulin delivery (CSII/AID) records, with 64 studies included. Eighteen studies assessed CGM accuracy, reporting mean absolute relative difference (MARD) values ranging from 8.1% to 29%, with over 97% of readings falling within Clarke error grid zones A or B. Thirteen studies compared glycemic markers, finding that HbA<sub>1c</sub> underestimated glucose by 7.3 mmol/mol, while glycated albumin showed a stronger correlation (r = 0.508). Four studies reported on dialysis effects, showing that people on automated peritoneal dialysis (APD) had lower mean glucose levels (181 &#177; 64 mg/dL) compared to continuous ambulatory peritoneal dialysis (CAPD) (238 &#177; 67 mg/dL; <italic toggle="yes">P</italic> &lt; .05). Eleven studies evaluating diabetes treatment efficacy using CGM found that dulaglutide significantly reduced glucose CV from 28.1% to 19.8% (<italic toggle="yes">P</italic> = .003). Twenty-two studies examining glycemic outcomes reported that TIR was lower on dialysis days (80.2%, <italic toggle="yes">P</italic> = .02). Finally, four AID studies reported TIR improvements of up to 37.6% and a 1.5 mmol/L reduction in glucose (<italic toggle="yes">P</italic> = .003).</p></sec><sec id="section4-19322968251353811"><title>Conclusion:</title><p>This review highlights the potential of CGM and AID to improve diabetes outcomes in people on dialysis. While their clinical utility is evident, broader access and further research are needed to optimize their use in this high-risk population.</p></sec></abstract><kwd-group><kwd>continuous glucose monitoring</kwd><kwd>CGM</kwd><kwd>insulin pump therapy</kwd><kwd>CSII</kwd><kwd>AID</kwd><kwd>diabetes</kwd><kwd>dialysis</kwd><kwd>hemodialysis</kwd><kwd>peritoneal dialysis</kwd><kwd>glycemic control</kwd><kwd>diabetes technology</kwd><kwd>scoping review</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section5-19322968251353811"><title>Introduction</title><p>Diabetes is one of the leading causes of end-stage kidney disease (ESKD) in many countries worldwide.<sup>
<xref rid="bibr1-19322968251353811" ref-type="bibr">1</xref>
</sup> As the incidence of diabetes rises, so too does the number of individuals with both diabetes and ESKD who require kidney replacement therapy (KRT). The limited availability of organs for transplantation, coupled with the cardiovascular comorbidities associated with diabetes, often restricts eligibility for kidney transplantation. Consequently, hemodialysis (HD) or peritoneal dialysis (PD) is frequently the only viable treatment options for many individuals. Despite significant advances in diabetes care, those with diabetes undergoing dialysis experience a reduced quality of life and a high burden of hypoglycemia and hyperglycemia<sup><xref rid="bibr2-19322968251353811" ref-type="bibr">2</xref>
<xref rid="bibr3-19322968251353811" ref-type="bibr"/><xref rid="bibr4-19322968251353811" ref-type="bibr"/>-<xref rid="bibr5-19322968251353811" ref-type="bibr">5</xref></sup> and hypoglycemia unawareness.<sup><xref rid="bibr6-19322968251353811" ref-type="bibr">6</xref>,<xref rid="bibr7-19322968251353811" ref-type="bibr">7</xref></sup></p><p>Managing diabetes in individuals with ESKD undergoing KRT presents unique challenges. Traditional glycemic management strategies can be less effective due to altered insulin pharmacokinetics and the dietary restrictions associated with ESKD.<sup>
<xref rid="bibr8-19322968251353811" ref-type="bibr">8</xref>
</sup> The ESKD is also linked with impaired kidney gluconeogenesis, a weakened counterregulatory hormonal response, malnutrition, insulin resistance, and impaired beta-cell function.<sup>
<xref rid="bibr9-19322968251353811" ref-type="bibr">9</xref>
</sup> As such, health care providers must navigate a complex landscape to maintain optimal glycemic levels in this population. High glucose levels can lead to increased thirst and fluid retention between dialysis sessions, contributing to fluid overload and higher mortality rates. These increased fluid gains can also affect dialysis tolerance, cause unpleasant hypotensive episodes, and prolong recovery time.<sup><xref rid="bibr10-19322968251353811" ref-type="bibr">10</xref>
<xref rid="bibr11-19322968251353811" ref-type="bibr"/>-<xref rid="bibr12-19322968251353811" ref-type="bibr">12</xref></sup></p><p>Technological advancements in diabetes management, such as continuous glucose monitoring (CGM) systems, insulin pumps or continuous subcutaneous insulin infusion (CSII) or automated insulin delivery (AID), and data management applications, offer promising solutions to improve glycemic levels among people on dialysis. These technologies provide real-time insights into glucose levels and facilitate more tailored insulin delivery. By enabling people with diabetes to respond proactively to glucose fluctuations, these tools meet the dynamic needs of those managing multiple comorbidities. However, integrating diabetes technologies into dialysis settings presents challenges.<sup>
<xref rid="bibr13-19322968251353811" ref-type="bibr">13</xref>
</sup> Access to advanced diabetes management tools and specialized diabetes services remains limited for many individuals with ESKD.<sup><xref rid="bibr13-19322968251353811" ref-type="bibr">13</xref>,<xref rid="bibr14-19322968251353811" ref-type="bibr">14</xref></sup> As the field of diabetes technology evolves, it is crucial to explore its application within the dialysis population.</p><p>Diabetes management in dialysis populations is complex, yet the role of diabetes technologies remains unclear. While previous reviews focus on glycemic outcomes,<sup><xref rid="bibr15-19322968251353811" ref-type="bibr">15</xref>
<xref rid="bibr16-19322968251353811" ref-type="bibr"/>-<xref rid="bibr17-19322968251353811" ref-type="bibr">17</xref></sup> gaps remain in understanding their accuracy, effectiveness, and real-world use. Given the unique metabolic challenges of KRT, a focused review is essential to optimize care, improve outcomes, and address disparities in access to advanced diabetes technology.</p></sec><sec sec-type="methods" id="section6-19322968251353811"><title>Methods</title><sec id="section7-19322968251353811"><title>Aim of the Scoping Review</title><p>This review aims to map existing literature on diabetes technology use in people receiving dialysis, focusing on utilization, accuracy in the dialysis population, and effectiveness in diabetes management.</p></sec></sec><sec id="section8-19322968251353811"><title>Research Questions</title><list list-type="order" id="list1-19322968251353811"><list-item><p><bold>Research Question 1:</bold> What diabetes technologies have been studied in individuals on dialysis, and what are their intended purposes?</p></list-item><list-item><p><bold>Research Question 2:</bold> How accurate and effective are these technologies in managing glycemia in this population?</p></list-item></list><sec id="section9-19322968251353811"><title>Search Strategy and Information Sources</title><sec id="section10-19322968251353811"><title>Protocol and registration</title><p>This scoping review followed the Joanna Briggs Institute methodology. The reporting of items is in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for Scoping Reviews (PRISMA-ScR) reporting guidelines.<sup>
<xref rid="bibr18-19322968251353811" ref-type="bibr">18</xref>
</sup> The protocol was registered with the Open Science Framework at osf.io/tqvzg (<ext-link xlink:href="https://doi.org/10.17605/OSF.IO/N39BP" ext-link-type="uri">https://doi.org/10.17605/OSF.IO/N39BP</ext-link>).</p></sec><sec id="section11-19322968251353811"><title>Information sources</title><p>The search strategy was developed in collaboration with a research librarian. The databases searched included CINAHL, Medline, and Embase. The search was conducted on May 1, 2024, updated on August 28, 2024, and further updated in May 2025 to identify any subsequent publications. The first author carried out searches using the keywords and Medical Subject Headings (MeSH) terms specified in <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/19322968251353811" ext-link-type="uri">Supplemental File 1</ext-link>. No restrictions were applied regarding publication date, study design, or country. The search was conducted in Medline (Ovid) and subsequently translated to the other databases. In addition, the reference lists of the included articles were reviewed to identify other potential studies. Our full search strategy is included in the <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/19322968251353811" ext-link-type="uri">Supplemental File 1</ext-link>.</p></sec></sec><sec id="section12-19322968251353811"><title>Study Selection and Eligibility Criteria</title><sec id="section13-19322968251353811"><title>Study selection</title><p>Articles were uploaded to the online systematic review platform, Covidence, for screening. Duplicates were detected and removed. The titles and abstracts of all studies were then screened by three primary reviewers (HHH-A, JNS, KC) to determine eligibility for full-text review. The primary reviewers conducted full-text assessments to identify studies that met the inclusion criteria. Any disagreements between the primary reviewers were discussed with a fourth, fifth, and sixth reviewer to reach a final decision.</p></sec><sec id="section14-19322968251353811"><title>Eligibility criteria</title><sec id="section15-19322968251353811"><title>Inclusion criteria</title><p>Studies conducted on adult people (age &#8805;18 years) focused on the use of diabetes technology such as CGM or CSII or AID undergoing dialysis with diabetes:</p><list list-type="order" id="list2-19322968251353811"><list-item><p>Research articles, clinical trials, clinical audits, abstracts, conference proceedings, case studies, and observational studies comparing the efficacy of diabetes technology interventions (CGM and/or CSII or AID with usual care in people with diabetes on dialysis).</p></list-item><list-item><p>Studies published in English.</p></list-item></list></sec><sec id="section16-19322968251353811"><title>Exclusion criteria</title><list list-type="order" id="list3-19322968251353811"><list-item><p>Studies that did not specifically assess the effects of diabetes technology interventions in dialysis population.</p></list-item><list-item><p>Studies that assessed diabetes technology intervention in the kidney transplant population.</p></list-item><list-item><p>Studies evaluating diabetes technology in mixed cohorts of dialysis and transplant population were excluded from this review if data specific to the dialysis subgroup could not be distinctly separated.</p></list-item><list-item><p>Systematic reviews or literature reviews.</p></list-item><list-item><p>Editorials or opinion pieces.</p></list-item><list-item><p>Studies published in languages other than English.</p></list-item></list></sec></sec></sec><sec id="section17-19322968251353811"><title>Data Extraction and Synthesis</title><sec id="section18-19322968251353811"><title>Charting the data</title><p>Three reviewers (HHH-A, JNS, KC) developed the data extraction table, which was reviewed by the senior authors (AF, DCW, JK). HHH-A guided JS and KC in the data extraction process and subsequently verified the extracted data. The senior authors (AF, JK) provided feedback on the final literature tables. The development and completion of these tables allowed us to summarize and synthesize the data effectively.</p></sec><sec id="section19-19322968251353811"><title>Synthesis of results</title><p>The study characteristics, methods, and outcomes were organized in a tabular format. Given the heterogeneity of the included studies, the extracted data were compiled to provide a comprehensive overview of each study, detailing the purpose and use of diabetes technologies and the reported outcomes in a standardized format. This information informed a narrative review that examined key aspects of the identified interventions, including the validation of CGM accuracy in dialysis populations, comparisons between CGM and traditional glycemic markers, the impact of dialysis on glucose profiles, the use of CGM to assess the efficacy of diabetes treatments, CGM-based evaluations of glycemic outcomes, and the application of AID systems in the dialysis population.</p></sec></sec></sec><sec sec-type="results" id="section20-19322968251353811"><title>Results</title><sec id="section21-19322968251353811"><title>Study Characteristics</title><p>A systematic search of electronic databases identified a total of 1060 studies on CGM/AID and 1467 studies on insulin infusion (CSII/AID). After the automatic removal of 345 duplicates related to CGM and 310 related to CSII or AID using Covidence review manager, 64 studies were retained. These were selected following a manual screening of titles, abstracts, and full texts by the reviewers. The study screening and selection process is illustrated in the PRISMA diagram (<xref rid="fig1-19322968251353811" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="fig1-19322968251353811" orientation="portrait"><label>Figure 1.</label><caption><p>Flow diagram of study selection.</p></caption><alt-text>Provide a detailed action breakdown of the study selection flow diagram including steps, inputs and outputs, and overall process/results.</alt-text><graphic position="float" orientation="portrait" xlink:href="10.1177_19322968251353811-fig1.jpg"/></fig><p>All included studies were published between 2003 and 2025, with the majority conducted in Europe (the United Kingdom, Denmark, France, Italy, Spain, Greece, Romania, Poland, Switzerland), Asia (Japan, China, India, Korea, Hong Kong, Bangladesh), North America (the United States of America), South America (Colombia, Brazil), and Australia. Samples ranged from 1 to 153 people, with follow-up durations from 4 hours to 12 months. Most participants were aged between 35 and 85 years, with 60% to 80% being male. Study designs comprised cohort (n = 27), clinical trials (n = 10), post hoc analyses (n = 5), cross-sectional (n = 9), case reports/series (n = 8), and pilot study (n = 5). Most focused on type 2 diabetes (n = 42): eight involved type 1, and 14 included mixed or unspecified types. The HD was the dominant modality (n = 46), followed by PD (n = 16) and both (n = 2). Technologies evaluated included CGMS (Dexcom G6, FreeStyle Libre, iPro2, Guardian Sensor 3) and closed-loop systems. Primary outcomes included device accuracy (Mean Absolute Relative Difference [MARD], Bland-Altman, error grids), glycemic metrics (time in range [TIR], variability, HbA<sub>1c</sub>), hypoglycemia detection, and AID safety, feasibility, and acceptability. <xref rid="table1-19322968251353811" ref-type="table">Table 1</xref> summarizes the study characteristics.</p><table-wrap position="float" id="table1-19322968251353811" orientation="portrait"><label>Table 1.</label><caption><p>Study Characteristics.</p></caption><alternatives><graphic position="float" orientation="portrait" xlink:href="10.1177_19322968251353811-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Number</th><th align="center" rowspan="1" colspan="1">Author and country</th><th align="center" rowspan="1" colspan="1">Study design/period of follow-up</th><th align="center" rowspan="1" colspan="1">Participants characteristics</th><th align="center" rowspan="1" colspan="1">Diabetes technology interventions</th><th align="center" rowspan="1" colspan="1">Outcomes</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1.</td><td rowspan="1" colspan="1">Avari et al,<sup>
<xref rid="bibr19-19322968251353811" ref-type="bibr">19</xref>
</sup> UK</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort study<break/><bold>Follow-up</bold>: 18 months</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 40<break/><bold>Diabetes type:</bold> Any form of diabetes<break/><bold>Age:</bold> 64.7 Median<break/><bold>Sex:</bold> 30 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> Assess CGM accuracy vs reference glucose<break/><bold>Type of diabetes technology:</bold> DexcomeG6 &amp; FreeStyle Libre 1<break/><bold>Dialysis Modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: To compare MARD (%) of Dexcom G6 and FreeStyle Libre 1 against reference YSI glucose values during HD</td></tr><tr><td rowspan="1" colspan="1">2.</td><td rowspan="1" colspan="1">Bally et al,<sup>
<xref rid="bibr20-19322968251353811" ref-type="bibr">20</xref>
</sup> UK</td><td rowspan="1" colspan="1"><bold>Design:</bold> Post hoc analysis<break/><bold>Follow-up</bold>: 15 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 17<break/><bold>Diabetes type</bold>: T2D<break/><bold>Age</bold>: 73 &#177; 8 (Treatment group) 67 &#177; 10 (Conventional therapy group)<break/><bold>Sex:</bold> 77% male (Treatment group), 63% male (Conventional therapy group)</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: Compare closed-loop vs standard insulin therapy<break/><bold>Type of diabetes technology:</bold> Closed loop: Dana R pump &amp; a model predictive algorithm, with CGM: FreeStyle Navigator II<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Time spent at glucose level in target glucose range</td></tr><tr><td rowspan="1" colspan="1">3.</td><td rowspan="1" colspan="1">Bomholt et al,<sup>
<xref rid="bibr21-19322968251353811" ref-type="bibr">21</xref>
</sup> Denmark</td><td rowspan="1" colspan="1"><bold>Design:</bold> Case-control Study<break/><bold>Follow-up</bold>: 9 months</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 23<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 69.7 (63.3-73.6)<break/><bold>Sex:</bold> 18 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> Evaluate HbA<sub>1c</sub> and fructosamine vs CGM<break/><bold>Type of diabetes technology:</bold> DexcomeG6<break/><bold>Dialysis Modality:</bold> PD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: Difference in Mean Glucose values, Glucose variability</td></tr><tr><td rowspan="1" colspan="1">4.</td><td rowspan="1" colspan="1">Bomholt et al,<sup>
<xref rid="bibr22-19322968251353811" ref-type="bibr">22</xref>
</sup> Denmark</td><td rowspan="1" colspan="1"><bold>Design:</bold> Post hoc analysis<break/><bold>Follow-up</bold>: 3 months</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 24<break/><bold>Diabetes type</bold>: T2D<break/><bold>Age:</bold> Not stated<break/><bold>Sex:</bold> 21 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To evaluate whether liraglutide, compared to placebo treatment<break/><bold>Type of diabetes technology:</bold> CGM (iPro2)<break/><bold>Dialysis Modality:</bold> PD &amp;HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Time in range; hypoglycemia; HbA<sub>1c</sub></td></tr><tr><td rowspan="1" colspan="1">5.</td><td rowspan="1" colspan="1">Bomholt et al,<sup>
<xref rid="bibr23-19322968251353811" ref-type="bibr">23</xref>
</sup> Denmark</td><td rowspan="1" colspan="1"><bold>Design:</bold> Case-control study<break/><bold>Period of follow-up</bold>: 10 months</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 66 (30 HD &amp; 36 Control)<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> Not stated<break/><bold>Sex:</bold> Not stated</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> Compare HbA1c and fructosamine vs CGM<bold>Type of diabetes technology:</bold> CGM iPro2<break/><bold>Dialysis Modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Difference in glycemic markers and sensor glucose</td></tr><tr><td rowspan="1" colspan="1">6.</td><td rowspan="1" colspan="1">Bomholt et al,<sup>
<xref rid="bibr24-19322968251353811" ref-type="bibr">24</xref>
</sup> Denmark</td><td rowspan="1" colspan="1"><bold>Design:</bold> Post hoc analysis<break/><bold>Follow-up</bold>: 7 months</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 27<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 66.4 (&#177;11.5)<break/><bold>Sex:</bold> 22 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> Evaluate glucose variation on dialysis vs non-dialysis days using CGM<break/><bold>Type of diabetes technology:</bold> CGMS iPro2<break/><bold>Dialysis Modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: Time-in-range, mean glucose, and glucose variability on dialysis vs non-dialysis days</td></tr><tr><td rowspan="1" colspan="1">7.</td><td rowspan="1" colspan="1">Boughton et al,<sup>
<xref rid="bibr25-19322968251353811" ref-type="bibr">25</xref>
</sup> UK</td><td rowspan="1" colspan="1"><bold>Design:</bold> Randomized crossover trial.<break/><bold>Follow-up:</bold> 20 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 26<break/><bold>Diabetes type</bold>: T2D<break/><bold>Age:</bold> Mean 68&#8201;&#177;&#8201;11<break/><bold>Sex:</bold> 17 Male</td><td rowspan="1" colspan="1"><bold>Purpose:</bold> Assess safety and efficacy of closed-loop vs standard insulin therapy in T2D on dialysis<break/><bold>Type of diabetes technology:</bold> Cambridge closed-loop system with masked CGM<break/><bold>Dialysis modality:</bold> PD or HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> The proportion of time sensor glucose remained within the target range of 5.6 to 10.0 mmol/L.</td></tr><tr><td rowspan="1" colspan="1">8.</td><td rowspan="1" colspan="1">Chantrel et al,<sup>
<xref rid="bibr26-19322968251353811" ref-type="bibr">26</xref>
</sup> France</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort observational study<break/><bold>Follow-up</bold>: 3 months</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 33<break/><bold>Diabetes type</bold>: T2D<break/><bold>Age</bold>: 66 &#177; 8 years<break/><bold>Sex:</bold> 19 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: Investigate impact of dialysis on glucose profiles in diabetes using CGM<break/><bold>Type of diabetes technology:</bold> CGM<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: CGM parameters compared during and outside dialysis sessions.</td></tr><tr><td rowspan="1" colspan="1">9.</td><td rowspan="1" colspan="1">Chantrel et al,<sup>
<xref rid="bibr27-19322968251353811" ref-type="bibr">27</xref>
</sup> France</td><td rowspan="1" colspan="1"><bold>Design:</bold> Non interventional study<break/><bold>Follow-up</bold>: 11 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 60<break/><bold>Diabetes type:</bold> Not specified<break/><bold>Age:</bold> 70 &#177; 11 years<break/><bold>Sex:</bold> Not reported</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> Describe routine diabetes and glycemic monitoring parameters using CGM<break/><bold>Technology:</bold> FreeStyle Free Pro<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Mean blood glucose level, percentage of blood glucose level: &lt; 0.70 g/dL TBR, between 0.70 and 1.80 g/dL TIR, and &gt; 1.80 g/dL TAR</td></tr><tr><td rowspan="1" colspan="1">10.</td><td rowspan="1" colspan="1">Chaudhry et al,<sup>
<xref rid="bibr28-19322968251353811" ref-type="bibr">28</xref>
</sup> UK</td><td rowspan="1" colspan="1"><bold>Design:</bold> Case series<break/><bold>Follow-up</bold>: &#8805; 14 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 4<break/><bold>Diabetes type:</bold> T1D<break/><bold>Age</bold>: Mean age 54 years (35&#8211;78 years).<break/><bold>Sex</bold>: 1 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: Evaluate automated insulin delivery in T1D patients undergoing hemodialysis<break/><bold>Type of diabetes technology</bold>: Medtronic MiniMed 780G AID and/or CGM<break/><bold>Dialysis Modality</bold>: HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: Difference in time-in-range (TIR) defined as 3.9-10 mmol/L (70-180 mg/dL).</td></tr><tr><td rowspan="1" colspan="1">11.</td><td rowspan="1" colspan="1">Divani et al,<sup>
<xref rid="bibr29-19322968251353811" ref-type="bibr">29</xref>
</sup> Greece</td><td rowspan="1" colspan="1"><bold>Design:</bold> Prospective observational study<break/><bold>Follow-up</bold>: 10 months</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 37<break/><bold>Diabetes type:</bold> Not specified<break/><bold>Age:</bold> 62.0 &#177; 17.2<break/><bold>Sex:</bold> 20 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> Assess albumin GA and glycated serum protein GSP as alternatives to HbA<sub>1c</sub> using CGM as reference<break/><bold>Type of diabetes technology:</bold> CGM<break/><bold>Dialysis Modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Evaluation of the accuracy of alternative glycemic biomarkers (such as GA and GSP) compared to HbA<sub>1c</sub> based on extensive interstitial glucose measurements obtained over a 7-day CGM period.</td></tr><tr><td rowspan="1" colspan="1">12.</td><td rowspan="1" colspan="1">Gai et al,<sup>
<xref rid="bibr30-19322968251353811" ref-type="bibr">30</xref>
</sup> Italy</td><td rowspan="1" colspan="1"><bold>Design:</bold> Observational study<break/><bold>Follow-up</bold>: 6 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 12<break/><bold>Diabetes type:</bold> Not specified<break/><bold>Age:</bold> 61.8 &#177; 13.9 years<break/><bold>Sex:</bold> 9 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> Assess glycemic control and monitor interstitial glucose over 6 days<break/><bold>Type of diabetes technology</bold>: CGM iPro<break/><bold>Dialysis Modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Changes in glycemia by capillary blood glucose and CGM</td></tr><tr><td rowspan="1" colspan="1">13.</td><td rowspan="1" colspan="1">Genua et al,<sup>
<xref rid="bibr31-19322968251353811" ref-type="bibr">31</xref>
</sup> Spain</td><td rowspan="1" colspan="1"><bold>Design:</bold> Prospective observational study.<break/><bold>Follow-up:</bold> 14 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 16<break/><bold>Diabetes type:</bold> 14 T2D, 1 T1D, and 1 other diabetes<break/><bold>Age:</bold> 68 <bold>&#177;</bold> 13<break/><bold>Sex:</bold> 11 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> Assess FreeStyle Libre accuracy, hydration status correlation, and patient satisfaction<break/><bold>Types of diabetes technology</bold>: FreeStyle Libre (flash glucose monitor)<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: MARD</td></tr><tr><td rowspan="1" colspan="1">14.</td><td rowspan="1" colspan="1">G&#243;mez et al,<sup>
<xref rid="bibr32-19322968251353811" ref-type="bibr">32</xref>
</sup> Colombia</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort interventional study<break/><bold>Follow-up</bold>: 6-day</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 47<break/><bold>Diabetes type:</bold> 4 T1D and 43 T2D<break/><bold>Age</bold>: 58.57 &#177; 11.49<break/><bold>Sex:</bold> 26 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: Evaluate effects of education and basal-bolus insulin on glycemic control<break/><bold>Type of diabetes technology:</bold> CGM: iPro2<break/><bold>Dialysis modality</bold>: PD (7 CAPD &amp;40 APD)</td><td rowspan="1" colspan="1"><bold>Primary</bold>: CGM parameters and HbA<sub>1c</sub> before and after an educational program and a basal-bolus insulin regimen</td></tr><tr><td rowspan="1" colspan="1">15.</td><td rowspan="1" colspan="1">Hayashi et al,<sup>
<xref rid="bibr33-19322968251353811" ref-type="bibr">33</xref>
</sup> Japan</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort study<break/><bold>Follow-up</bold>: 48 hours</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 77<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 62 years<break/><bold>Sex:</bold> 54 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> Assess glycemic differences between well-controlled vs hypoglycemic patients (TBR &#8805;4%)<break/><bold>Type of diabetes technology:</bold> CGMS<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: Glycemic parameters (Time in Range, Time Below Range, Time above range and mean glucose and coefficient of variation).</td></tr><tr><td rowspan="1" colspan="1">16.</td><td rowspan="1" colspan="1">Hayashi et al,<sup>
<xref rid="bibr34-19322968251353811" ref-type="bibr">34</xref>
</sup> Japan</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cross-sectional study<break/><bold>Follow-up</bold>: 2 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 107<break/><bold>Diabetes type:</bold> T2D<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age</bold>: 62 &#177; 12 years<break/><bold>Sex:</bold> 74 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To examine associations between TIR, glycemic markers, and diabetic microangiopathy.<break/><bold>Type of diabetes technology:</bold> CGMS Gold or CGM iPro2<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: Analyze glycemic markers from CGM data and HbA<sub>1c</sub> in relation to history or clinical features of microangiopathies</td></tr><tr><td rowspan="1" colspan="1">17.</td><td rowspan="1" colspan="1">Hissa et al,<sup>
<xref rid="bibr35-19322968251353811" ref-type="bibr">35</xref>
</sup> Brazil</td><td rowspan="1" colspan="1"><bold>Design:</bold> Prospective study<break/><bold>Follow-up:</bold> 3 weeks</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 12<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 66.8 &#177; 8.0<break/><bold>Sex:</bold> 8 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> Evaluate FreeStyle Libre accuracy vs SMBG pre- and post-dialysis<bold>Type of diabetes technology:</bold> Free style Libre<break/><bold>Dialysis Modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> To compare pre- and post-dialysis measurements by CGM and SMBG</td></tr><tr><td rowspan="1" colspan="1">18.</td><td rowspan="1" colspan="1">Horne et al,<sup>
<xref rid="bibr36-19322968251353811" ref-type="bibr">36</xref>
</sup> UK</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort study<break/><bold>Follow-up</bold>: 14 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 69<break/><bold>Diabetes type:</bold> 14 T1D and 55 T2D<break/><bold>Age</bold>: 64 (33-83)<break/><bold>Sex:</bold> 42 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To validate CGM against capillary and serum glucose in patients with diabetes on HD<break/><bold>Type of diabetes technology:</bold> CGM: Libre FreeStyle Pro<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: CGM vs SMBG or laboratory glucose</td></tr><tr><td rowspan="1" colspan="1">19.</td><td rowspan="1" colspan="1">Hu et al,<sup>
<xref rid="bibr37-19322968251353811" ref-type="bibr">37</xref>
</sup> China</td><td rowspan="1" colspan="1"><bold>Design:</bold> Non-randomized controlled trial<break/><bold>Follow-up</bold>: 14 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 52<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age</bold>: 60.89 &#177; 10.57<break/><bold>Sex:</bold> 38 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: Investigate TIR utility in diabetes management and glycemic optimization via flash glucose monitoring system.<break/><bold>Type of diabetes technology:</bold> CGM: FreeStyle Libre<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: Glucose variability: CV, SD, MAGE, and largest amplitude of excursions</td></tr><tr><td rowspan="1" colspan="1">20.</td><td rowspan="1" colspan="1">Javherani et al,<sup>
<xref rid="bibr38-19322968251353811" ref-type="bibr">38</xref>
</sup> India</td><td rowspan="1" colspan="1"><bold>Design</bold>: A cross-sectional pilot study<break/><bold>Follow-up</bold>: N/A</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 10<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 60.4 &#177; 10.5 years<break/><bold>Sex:</bold> 7 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To use ambulatory glucose profile to study patterns before, during, and after dialysis<break/><bold>Diabetes technology:</bold> Flash glucose monitor<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Glycemic patterns in subjects with type 2 diabetes mellitus and ESRD undergoing hemodialysis.</td></tr><tr><td rowspan="1" colspan="1">21.</td><td rowspan="1" colspan="1">Jin et al,<sup>
<xref rid="bibr39-19322968251353811" ref-type="bibr">39</xref>
</sup> China</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort study<break/><bold>Follow-up</bold>: 72 hours</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 46<break/><bold>Diabetes type:</bold> 36 T2D<break/><bold>Age</bold>: 62 &#177; 13 (diabetes group)<break/><bold>Sex:</bold> 29 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To characterize blood<break/>fluctuations during HD using CGM<break/><bold>Type of diabetes technology:</bold> CGM<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: Glycemic parameters (mean, standard deviation, MAGE) including peri-hemodialysis</td></tr><tr><td rowspan="1" colspan="1">22.</td><td rowspan="1" colspan="1">Joubert et al,<sup>
<xref rid="bibr40-19322968251353811" ref-type="bibr">40</xref>
</sup> France</td><td rowspan="1" colspan="1"><bold>Design:</bold> Pilot study<break/><bold>Follow-up</bold>: 12 weeks</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 15<break/><bold>Diabetes type:</bold> 2 T1D, 9 T2D, 4 secondary diabetes<break/><bold>Age</bold>: 60.9 &#177; 14.8<break/><bold>Sex:</bold> 8 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To evaluate the impact of repeated CGM sessions on glycemic levels in dialysis patients with diabetes.<break/><bold>Type of diabetes technology:</bold> CGM iPro2<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: Mean CGM glucose value at the end of each period, compared to baseline.</td></tr><tr><td rowspan="1" colspan="1">23.</td><td rowspan="1" colspan="1">Jung et al,<sup>
<xref rid="bibr41-19322968251353811" ref-type="bibr">41</xref>
</sup> Korea</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cross-sectional observational study<break/><bold>Follow-up</bold>: 6 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 9<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 67 &#177; 9 years<break/><bold>Sex</bold>: 3 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To describe glucose profiles and hypoglycemia associated with HD in diabetes patients using a CGM system.<break/><bold>Diabetes technology:</bold> CGM<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Glucose profiles on/off HD; episodes of hypoglycemia</td></tr><tr><td rowspan="1" colspan="1">24.</td><td rowspan="1" colspan="1">Kaminski et al,<sup>
<xref rid="bibr42-19322968251353811" ref-type="bibr">42</xref>
</sup> USA</td><td rowspan="1" colspan="1"><bold>Design:</bold> Pilot prospective study<break/><bold>Follow-up:</bold> Not reported</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 40<break/><bold>Diabetes type:</bold> 20 with &#8220;burnt-out&#8221; diabetes<break/><bold>Age</bold>: Not reported<break/><bold>Sex</bold>: Not reported</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To assess glycemic control by CGM metrics and glycemic markers in patients on hemodialysis with burnt-out diabetes<break/><bold>Diabetes technology:</bold> Dexcom G6 CGM.<break/><bold>Dialysis modality</bold>: HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: Glycemic control by measured by CGM metrics and glycemic markers</td></tr><tr><td rowspan="1" colspan="1">25.</td><td rowspan="1" colspan="1">Kashem et al,<sup>
<xref rid="bibr43-19322968251353811" ref-type="bibr">43</xref>
</sup> Bangladesh</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort study<break/><bold>Follow-up</bold>: 4 hours</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 14<break/><bold>Diabetes type:</bold> Not specified<break/><bold>Age:</bold> Not reported<break/><bold>Sex:</bold> Not reported</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To validate CGMS during dialysis comparing readings to laboratory blood levels intra-dialysis with samples taken every 15 minutes.<break/><bold>Type of diabetes technology:</bold>
<break/>CGMS (Dexcom G4)<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: CGM data and laboratory blood glucose measurements.</td></tr><tr><td rowspan="1" colspan="1">26.</td><td rowspan="1" colspan="1">Kazempour-Ardebili et al<sup>
<xref rid="bibr44-19322968251353811" ref-type="bibr">44</xref>
</sup> UK</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cross-sectional study.<break/><bold>Follow-up:</bold> 48 hours</td><td rowspan="1" colspan="1"><bold>Sample</bold>: 17<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age</bold>: 61.5 &#177; 8.8 years (42&#8211;79 years)<break/><bold>Sex:</bold> 13 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To compare 48-hour CGM glucose profiles on vs off dialysis, explore associations with self-reported food intake, and assess the utility of 48-hour CGM for glycemic monitoring.<break/><bold>Diabetes technology:</bold> GlucoDay CGM<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Glucose profiles from days on and off dialysis using 48-hour CGM in type 2 patients with diabetes</td></tr><tr><td rowspan="1" colspan="1">27.</td><td rowspan="1" colspan="1">Kepenekian et al,<sup>
<xref rid="bibr45-19322968251353811" ref-type="bibr">45</xref>
</sup> France</td><td rowspan="1" colspan="1"><bold>Design:</bold> Pilot prospective multicenter study<break/><bold>Follow-up:</bold> 12 months</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 28<break/><bold>Diabetes type</bold>: T2D<break/><bold>Age:</bold> Not reported<break/><bold>Sex:</bold> Not reported</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To evaluate the contribution of CGM to the management of insulin regimen.<break/><bold>Diabetes technology:</bold> CGM (Navigator)<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> HbA<sub>1c</sub> levels and mean CGM glucose values</td></tr><tr><td rowspan="1" colspan="1">28.</td><td rowspan="1" colspan="1">Lee et al,<sup>
<xref rid="bibr46-19322968251353811" ref-type="bibr">46</xref>
</sup> South Korea</td><td rowspan="1" colspan="1"><bold>Design:</bold> Prospective study<break/><bold>Follow-up:</bold> 13 weeks</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 18<break/><bold>Diabetes type</bold>: 1 T1D<break/><bold>Age:</bold> 62.0 &#177; 11.2<break/><bold>Sex:</bold> 13 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To assess CGM usefulness for glycemic control and variability stabilization.<break/><bold>Type of diabetes technology:</bold> CGM iPro2 &amp; Enlite glucose sensors<break/><bold>Dialysis Modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Changes in glycemia markers and CGM metrics, glycemic variability, standard deviation (SD), and % coefficient variation (%CV)</td></tr><tr><td rowspan="1" colspan="1">29.</td><td rowspan="1" colspan="1">Lee et al,<sup>
<xref rid="bibr47-19322968251353811" ref-type="bibr">47</xref>
</sup> Taiwan</td><td rowspan="1" colspan="1"><bold>Design:</bold> Non- interventional study<break/><bold>Follow-up:</bold> 3 days</td><td rowspan="1" colspan="1"><bold>Sample</bold>: 25<break/><bold>Diabetes type:</bold> Not specified<break/><bold>Age:</bold> 59 &#177; 13 years<break/><bold>Sex:</bold> 13 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To test accuracy of HbA<sub>1c</sub>, fasting glucose, fructosamine, AlbF, and GA as markers.<break/><bold>Diabetes technology:</bold> CGMS<break/><bold>Dialysis modality:</bold> PD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Mean values of various glycemic control parameters</td></tr><tr><td rowspan="1" colspan="1">30.</td><td rowspan="1" colspan="1">Ling et al,<sup>
<xref rid="bibr48-19322968251353811" ref-type="bibr">48</xref>
</sup> Hong Kong</td><td rowspan="1" colspan="1"><bold>Design:</bold> Exploratory analysis<break/><bold>Follow-up:</bold> 14 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 30<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 64.7 &#177; 5.6 years,<break/><bold>Sex:</bold> 23 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: Investigate CGM accuracy correlation with body composition and Hb in CAPD patients<break/><bold>Diabetes technology:</bold> CGM Guardian Sensor 3<break/><bold>Dialysis modality:</bold> PD <bold>(</bold>CAPD)</td><td rowspan="1" colspan="1"><bold>Primary:</bold> The mean absolute relative difference (MARD) between CGM&#8211;plasma YSI glucose pairs during the in-clinic session</td></tr><tr><td rowspan="1" colspan="1">31.</td><td rowspan="1" colspan="1">Mambelli et al,<sup>
<xref rid="bibr49-19322968251353811" ref-type="bibr">49</xref>
</sup> Italy</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort study<break/><bold>Follow-up:</bold> 12 weeks</td><td rowspan="1" colspan="1"><bold>Sample</bold>: 31<break/><bold>Diabetes type:</bold> 20 T2D<break/><bold>Age</bold>: 18-85 years (63.3 &#177; 2.8 for T2DM and 63.7 &#177; 4.5 for non-diabetics)<break/><bold>Sex:</bold> 22 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To compare Flash glucose monitoring to SMBG<break/><bold>Diabetes technology:</bold> Flash glucose monitoring<break/><bold>Dialysis Modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Relationship between Flash glucose monitoring and SMBG readings</td></tr><tr><td rowspan="1" colspan="1">32.</td><td rowspan="1" colspan="1">Marshall et al,<sup>
<xref rid="bibr50-19322968251353811" ref-type="bibr">50</xref>
</sup> UK</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort study<break/><bold>Follow-up:</bold> 3 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 8<break/><bold>Diabetes type</bold>: 5 T2D &amp; 3 T1D<break/><bold>Age:</bold> 52 years (Mean) (Range = 42-72).<break/><bold>Sex:</bold> Not reported</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To assess glycemic control under various peritoneal dialysis solutions<break/><bold>Diabetes technology:</bold> CGMS<break/><bold>Dialysis modality:</bold> PD <bold>(</bold>CAPD)</td><td rowspan="1" colspan="1"><bold>Primary</bold>: The effect of three differing peritoneal dialysis regimes on glycemic control</td></tr><tr><td rowspan="1" colspan="1">33.</td><td rowspan="1" colspan="1">Matoba et al,<sup>
<xref rid="bibr51-19322968251353811" ref-type="bibr">51</xref>
</sup> Japan</td><td rowspan="1" colspan="1"><bold>Design</bold>: Cohort study<break/><bold>Follow-up:</bold> 14 days</td><td rowspan="1" colspan="1"><bold>Sample</bold>: 13<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age</bold>: 61.6&#8239;&#177;&#8239;11.9<break/><bold>Sex:</bold> 9 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To compare flash glucose monitoring, CGM, and SMBG in T2D on HD<break/><bold>Diabetes technology</bold>: FreeStyle LibrePro, CGM iPro2<break/><bold>Dialysis modality</bold>: HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Correlations between SMBG and flash glucose monitoring and CGM</td></tr><tr><td rowspan="1" colspan="1">34.</td><td rowspan="1" colspan="1">Mayeda et al,<sup>
<xref rid="bibr52-19322968251353811" ref-type="bibr">52</xref>
</sup> USA</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort study<break/><bold>Period of follow-up</bold>: 10 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 153 (132 HD, 21 PD).<break/><bold>Diabetes type</bold>: Not specified<break/><bold>Age:</bold> 61 &#177; 14<break/><bold>Sex:</bold> Not reported</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To examine the prevalence, causes, and outcomes of dysglycemia in people dialysis.<break/><bold>Type of diabetes technology:</bold> Dexcom G6 CGM<break/><bold>Dialysis modality:</bold> PD or HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: Glycemic metrics (mean glucose, GMI, TIR, high/very high/low/very low)</td></tr><tr><td rowspan="1" colspan="1">35.</td><td rowspan="1" colspan="1">Meyer et al,<sup>
<xref rid="bibr53-19322968251353811" ref-type="bibr">53</xref>
</sup> UK</td><td rowspan="1" colspan="1"><bold>Study design</bold>: Cross- sectional study<break/><bold>Follow-up:</bold> 54 hours</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 23<break/><bold>Diabetes type:</bold> 22 T2D and 1 T1D<break/><bold>Age:</bold> 65.7 &#177; 9.4<break/><bold>Sex:</bold> 13 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To explore the relationship between CGM, HbA<sub>1c</sub>, glycated albumin, and other markers<break/><bold>Diabetes technology:</bold> CGM<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Relationship between HbA<sub>1c</sub>, glycated albumin, and other markers in persons with diabetes treated with hemodialysis</td></tr><tr><td rowspan="1" colspan="1">36.</td><td rowspan="1" colspan="1">Mirani et al,<sup>
<xref rid="bibr54-19322968251353811" ref-type="bibr">54</xref>
</sup> Italy</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort study<break/><bold>Follow-up</bold>: 2 days</td><td rowspan="1" colspan="1"><bold>Sample</bold>: 12<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 62.5&#8201;&#177;&#8201;9.9 years<break/><bold>Sex:</bold> 7 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To assess short-term variation in glucose metabolism in T2D patients on HD<break/><bold>Diabetes technology</bold>: CGM (GlucoDay)<break/><bold>Dialysis modality</bold>: HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Inter-day glycemic variability in insulin-treated T2D on HD</td></tr><tr><td rowspan="1" colspan="1">37.</td><td rowspan="1" colspan="1">Mori et al,<sup>
<xref rid="bibr55-19322968251353811" ref-type="bibr">55</xref>
</sup> Japan</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort study<break/><bold>Follow-up:</bold> 3 days</td><td rowspan="1" colspan="1"><bold>Sample</bold>: 10<break/><bold>Diabetes type</bold>: Not specified<break/><bold>Sex</bold>: Not reported<break/><bold>Age</bold>: Not reported</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To determine diurnal variations in blood glucose in PD.<break/><bold>Diabetes technology:</bold> CGM iPro2<break/><bold>Dialysis modality:</bold> PD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Diurnal variation; standard deviation of blood glucose vs dialysate-to-plasma ratio of creatinine and end-to-initial dialysate</td></tr><tr><td rowspan="1" colspan="1">38.</td><td rowspan="1" colspan="1">Mori et al,<sup>
<xref rid="bibr56-19322968251353811" ref-type="bibr">56</xref>
</sup> Japan</td><td rowspan="1" colspan="1"><bold>Design:</bold> Case report<break/><bold>Follow-up:</bold> 2 days</td><td rowspan="1" colspan="1"><bold>Sample</bold>: 1<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 68 years<break/><bold>Sex:</bold> 1 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: Visualize glucose fluctuation pre, during, and post dialysis<break/><bold>Diabetes Technology:</bold> CGM<break/><bold>Dialysis modality</bold>: HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Blood glucose levels before, during and after HD</td></tr><tr><td rowspan="1" colspan="1">39.</td><td rowspan="1" colspan="1">Munch et al,<sup>
<xref rid="bibr57-19322968251353811" ref-type="bibr">57</xref>
</sup> France</td><td rowspan="1" colspan="1"><bold>Design:</bold> Randomized Control trial<break/><bold>Follow-up:</bold> 12 weeks</td><td rowspan="1" colspan="1"><bold>Sample</bold>: 65<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 70.5&#8201;&#177;&#8201;8.5&#8201;years<break/><bold>Sex:</bold> 31 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To assess the effect of adding vildagliptin to insulin therapy using CGM<break/><bold>Diabetes technology</bold>: CGM iPro2<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Change in CGM glucose profiles and metabolic control</td></tr><tr><td rowspan="1" colspan="1">40.</td><td rowspan="1" colspan="1">Narasaki et al,<sup>
<xref rid="bibr58-19322968251353811" ref-type="bibr">58</xref>
</sup> USA</td><td rowspan="1" colspan="1"><bold>Design:</bold> Case report<break/><bold>Follow-up</bold>: N/A</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 1<break/><bold>Diabetes type:</bold> Not specified<break/><bold>Age:</bold> 49 years<break/><bold>Sex:</bold> 1 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To describe a patient with diabetes on HD in whom CGM improved glycemic control and reduced treatment burden<break/><bold>Diabetes technology:</bold> CGM Dexcom G6<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Change in glycemic control and patient-burden.</td></tr><tr><td rowspan="1" colspan="1">41.</td><td rowspan="1" colspan="1">Ng et al,<sup>
<xref rid="bibr59-19322968251353811" ref-type="bibr">59</xref>
</sup> Hong Kong</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort study<break/><bold>Follow-up</bold>: 14 days</td><td rowspan="1" colspan="1"><bold>Sample</bold>: 30<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 64.7 &#177; 5.6<break/><bold>Sex:</bold> 23 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To evaluate the performance of a real-time CGM in individuals with diabetes on PD.<break/><bold>Diabetes technology:</bold> CGM Guardian Sensor 3<break/><bold>Dialysis modality:</bold> PD (CAPD)</td><td rowspan="1" colspan="1"><bold>Primary:</bold> MARD between CGM-plasma Yellow Springs Instrument (YSI) glucose</td></tr><tr><td rowspan="1" colspan="1">42.</td><td rowspan="1" colspan="1">Oei et al,<sup>
<xref rid="bibr60-19322968251353811" ref-type="bibr">60</xref>
</sup> UK</td><td rowspan="1" colspan="1"><bold>Design</bold>: Case reports<break/><bold>Follow-up s</bold>: N/A</td><td rowspan="1" colspan="1"><bold>Sample</bold>: 3<break/><bold>Diabetes type:</bold> 2 T2D &amp; 1 T1D<break/><bold>Age:</bold> 56-60 (Range)<break/><bold>Sex</bold>: 3 Males</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To report differing CGM profiles despite similar HbA<sub>1c</sub> levels in patients on PD.<break/><bold>Diabetes technology:</bold> CGM Dexcom G4<break/><bold>Dialysis modality:</bold> PD (CAPD)</td><td rowspan="1" colspan="1"><bold>Primary:</bold> HbA<sub>1c</sub> levels vs CGM-derived glucose variability</td></tr><tr><td rowspan="1" colspan="1">43.</td><td rowspan="1" colspan="1">Okada et al,<sup>
<xref rid="bibr61-19322968251353811" ref-type="bibr">61</xref>
</sup> Japan</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort study.<break/><bold>Follow-up</bold>: 72 hours</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 20<break/><bold>Diabetes type:</bold>
<break/><bold>Age:</bold> 55 &#177; 10 years<break/><bold>Sex</bold>: 16 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To compare glucose variability in APD vs CAPD<break/><bold>Diabetic technology:</bold> CGMS<break/><bold>Dialysis modality:</bold> PD <bold>(</bold>APD and CAPD)</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Differences in glycemic variability between APD and CAPD</td></tr><tr><td rowspan="1" colspan="1">44.</td><td rowspan="1" colspan="1">Osonoi et al,<sup>
<xref rid="bibr62-19322968251353811" ref-type="bibr">62</xref>
</sup> Japan</td><td rowspan="1" colspan="1"><bold>Design:</bold> Pilot study<break/><bold>Follow-up</bold>: 3 days</td><td rowspan="1" colspan="1"><bold>Sample</bold>: 10<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 65.8 &#177;9.3 years<break/><bold>Sex:</bold> 9 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To assess if liraglutide dose adjustment is needed in people with diabetes on HD using CGM to evaluate pharmacokinetics, efficacy, and safety<break/><bold>Diabetic technology:</bold> CGM<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Efficacy of liraglutide in controlling blood glucose levels</td></tr><tr><td rowspan="1" colspan="1">45.</td><td rowspan="1" colspan="1">Popa et al,<sup>
<xref rid="bibr63-19322968251353811" ref-type="bibr">63</xref>
</sup> Romania</td><td rowspan="1" colspan="1"><bold>Design</bold>: Cross-sectional study<break/><bold>Follow-up:</bold> 3 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 31 comprising of PD+DM+(n = 11); PD+DM-(n = 9); PD-DM+(n = 11)<break/><bold>Diabetes type:</bold>
<break/><bold>Age:</bold> 65.8 &#177; 10.2; 60.2 &#177; 8.3; 57.6 &#177; 9.5<break/><bold>Sex:</bold> 12 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To assess CGM-based glycemic variability and the impact of glucose load and transport status<break/><bold>Diabetes technology:</bold> CGM Dexcom 7<break/>D<bold>ialysis modality:</bold> PD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> To compare glycemic variability among diabetic PD patients (PD+DM+), non-diabetic PD patients (PD+DM-), and patients with diabetes without PD (PD-DM+)</td></tr><tr><td rowspan="1" colspan="1">46.</td><td rowspan="1" colspan="1">Qayyum et al,<sup>
<xref rid="bibr64-19322968251353811" ref-type="bibr">64</xref>
</sup> UK</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort study<break/><bold>Follow-up:</bold> Not stated</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 60<break/><bold>Diabetes type:</bold> 5 T1D &amp; 55 T2D<break/><bold>Age:</bold> 60.2 &#177; 10.9 years<break/><bold>Sex:</bold> Not stated</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To compare glycated hemoglobin with CGM data in individuals on PD.<break/><bold>Diabetic technology:</bold> CGMS Dexcom G4<break/><bold>Dialysis modality:</bold> PD <bold>(</bold>CAPD and APD)</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Correlation between glycated hemoglobin and CGM</td></tr><tr><td rowspan="1" colspan="1">47.</td><td rowspan="1" colspan="1">Ramos et al,<sup>
<xref rid="bibr65-19322968251353811" ref-type="bibr">65</xref>
</sup> Brazil</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort study<break/><bold>Follow-up:</bold> 42 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 11<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 67.1 &#177; 6.7<break/><bold>Sex:</bold> 9 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To assess glycemic variability and hypoglycemia in individuals on HD using basal insulin<break/><bold>Diabetes technology:</bold> CGMS<break/><bold>Dialysis modality</bold>: HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: Glycemic variability</td></tr><tr><td rowspan="1" colspan="1">48.</td><td rowspan="1" colspan="1">Riveline et al,<sup>
<xref rid="bibr66-19322968251353811" ref-type="bibr">66</xref>
</sup> France</td><td rowspan="1" colspan="1"><bold>Design:</bold> Non-randomized comparative study<break/><bold>Follow-up</bold>: 4 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 58 (19 HD; 39 non-HD)<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> HD T2: 64 &#177; 10; non-HD T2: 65 &#177; 6<break/><bold>Sex:</bold> 33 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To evaluate the clinical performance of CGM in individuals with T2D on HD.<break/><bold>Diabetes technology</bold>: CGMS MiniMed<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Accuracy of CGMS in measuring glucose variability</td></tr><tr><td rowspan="1" colspan="1">49.</td><td rowspan="1" colspan="1">Rossi et al,<sup>
<xref rid="bibr67-19322968251353811" ref-type="bibr">67</xref>
</sup> Italy</td><td rowspan="1" colspan="1"><bold>Design:</bold> Case report<break/><bold>Follow-up:</bold> 1 year</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 1<break/><bold>Diabetes type:</bold> T1D<break/><bold>Age:</bold> 77 years<break/><bold>Sex:</bold> 1 Male</td><td rowspan="1" colspan="1"><bold>Purpose:</bold> Describe benefits of automated insulin delivery in complex cases.<break/><bold>Type of diabetes technology</bold>: Hybrid Closed Loop (Medtronic MiniMed 670G)<break/><bold>Dialysis modality</bold>: PD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: Time in range (TIR)</td></tr><tr><td rowspan="1" colspan="1">50.</td><td rowspan="1" colspan="1">Savu et al,<sup>
<xref rid="bibr68-19322968251353811" ref-type="bibr">68</xref>
</sup> Romania</td><td rowspan="1" colspan="1"><bold>Design</bold>: Prospective study comparing two non-randomized groups<break/><bold>Follow-up</bold>: 5 days</td><td rowspan="1" colspan="1"><bold>Sample</bold>: 14 (7 on Glargine and 7 on Detemir)<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 62.7 &#177; 3.2 (Glargine)<break/>70.8. &#177; 3.3 (Detemir)<break/><bold>Sex:</bold> 8 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To analyze the impact of basal insulin analogues on glucose variability in T2D during renal replacement therapy<break/><bold>Diabetes technology</bold>: CGMS Dexcom 7<break/><bold>Dialysis modality</bold>: HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Glucose variability</td></tr><tr><td rowspan="1" colspan="1">51.</td><td rowspan="1" colspan="1">Schwing et al,<sup>
<xref rid="bibr69-19322968251353811" ref-type="bibr">69</xref>
</sup> USA</td><td rowspan="1" colspan="1"><bold>Design</bold>: Cross-sectional study<break/><bold>Follow-up</bold>: 3 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 7<break/><bold>Diabetes type:</bold> T2D &amp; T1D<break/><bold>Age:</bold> Not provided<break/><bold>Sex:</bold> Not provided</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To assess minute-to-minute effect of high-dextrose peritoneal dialysate<break/><bold>Diabetes technology:</bold> CGMS MiniMed<break/><bold>Dialysis modality:</bold> PD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Glycemic outcome</td></tr><tr><td rowspan="1" colspan="1">52.</td><td rowspan="1" colspan="1">Skubala et al,<sup>
<xref rid="bibr70-19322968251353811" ref-type="bibr">70</xref>
</sup> Poland</td><td rowspan="1" colspan="1"><bold>Design:</bold> Non-randomized clinical trial<break/><bold>Follow-up</bold>: 3 months</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 43<break/><bold>Diabetes type:</bold> 30 unspecified diabetes<break/><bold>Age</bold>: study group 57.46 &#177; 12.46, control group 32.3 &#177; 9.21<break/><bold>Sex:</bold> 17 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To assess the impact of glucose-rich peritoneal fluids on daily glycemic profiles using CGM.<break/><bold>Diabetes technology:</bold> CGMS MiniMed<break/><bold>Dialysis modality:</bold> PD <bold>(</bold>CAPD)</td><td rowspan="1" colspan="1"><bold>Primar</bold>y: Glycemic outcomes</td></tr><tr><td rowspan="1" colspan="1">53.</td><td rowspan="1" colspan="1">Toyoda et al,<sup>
<xref rid="bibr71-19322968251353811" ref-type="bibr">71</xref>
</sup> Japan</td><td rowspan="1" colspan="1"><bold>Study design:</bold> Cohort study<break/><bold>Follow-up</bold>: 14 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 41<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 67.4 (&#177; 11.5)<break/><bold>Sex:</bold> 28 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To evaluate the accuracy of FreeStyle Libre in individuals with T2D undergoing HD.<break/><bold>Diabetes technology:</bold> FreeStyle Libre<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Accuracy of FreeStyle Libre as measured by the MARD over 14&#8201;days</td></tr><tr><td rowspan="1" colspan="1">54.</td><td rowspan="1" colspan="1">Ugamura et al,<sup>
<xref rid="bibr72-19322968251353811" ref-type="bibr">72</xref>
</sup> Japan</td><td rowspan="1" colspan="1"><bold>Design:</bold> Exploratory study<break/><bold>Follow-up:</bold> 6 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 12<break/><bold>Diabetes type</bold>: T2D<break/><bold>Age:</bold> 70.0 years (Median age)<break/><bold>Sex:</bold> 9 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To evaluate the efficacy and safety of dulaglutide in insulin-treated individuals with T2D on HD.<break/><bold>Diabetes technology:</bold> CGM iPro 2<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Changes from baseline over 24 weeks in mean and SD of blood glucose, MAGE (6-day CGM), glycated albumin, HbA<sub>1c</sub>, pre-dialysis glucose, and daily insulin dose</td></tr><tr><td rowspan="1" colspan="1">55.</td><td rowspan="1" colspan="1">Ushigome et al,<sup>
<xref rid="bibr73-19322968251353811" ref-type="bibr">73</xref>
</sup> Japan</td><td rowspan="1" colspan="1"><bold>Design</bold>: Case report<break/><bold>Follow-up:</bold> 1 week</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 18<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 46-76 (range)<break/><bold>Sex:</bold> 10 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To investigate whether estimated HbA<sub>1c</sub> from flash CGM reflects glycemic control in hemodialysis people with diabetes.<break/><bold>Diabetes technology:</bold> Flash Glucose Monitoring System<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Estimated hemoglobin A1c (eHbA<sub>1c</sub>) levels</td></tr><tr><td rowspan="1" colspan="1">56.</td><td rowspan="1" colspan="1">Villard et al,<sup>
<xref rid="bibr74-19322968251353811" ref-type="bibr">74</xref>
</sup> USA</td><td rowspan="1" colspan="1"><bold>Design&#8212;</bold>Pilot study<break/><bold>Follow-up</bold>:181 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 20<break/><bold>Diabetes type:</bold> Not specified<break/><bold>Age:</bold> 61.2 &#177; 11.6<break/><bold>Sex:</bold> 14 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To assess the accuracy of a factory-calibrated CGM in undergoing HD.<break/><bold>Diabetes technology:</bold> CGM Dexcom G6<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> MARD in blood glucose as measured by CGMS</td></tr><tr><td rowspan="1" colspan="1">57.</td><td rowspan="1" colspan="1">Wada et al,<sup>
<xref rid="bibr75-19322968251353811" ref-type="bibr">75</xref>
</sup> Japan</td><td rowspan="1" colspan="1"><bold>Design:</bold> Non-randomized clinical trial<break/><bold>Follow-up</bold>: 4 weeks</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 10<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 68.0 Mean<break/><bold>Sex:</bold> 8 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To evaluate the efficacy of teneligliptin using CGM in people with T2D on HD.<break/><bold>Diabetes technology:</bold> CGM<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Improvement of glycemic control evaluated by area under the curve (AUC)</td></tr><tr><td rowspan="1" colspan="1">58.</td><td rowspan="1" colspan="1">Wang et al,<sup>
<xref rid="bibr76-19322968251353811" ref-type="bibr">76</xref>
</sup> Australia</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cross-Sectional analysis<break/><bold>Follow-up:</bold> Not reported</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 10<break/><bold>Diabetes type:</bold> T1D<break/><bold>Age:</bold> 44 (Median age)</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To assess CGM accuracy in adults with T1D on HD during acute hospital stays, addressing limitations of traditional glucose monitoring.<break/><bold>Diabetes technology</bold>: FreeStyle Libre2 or Dexcom G6<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> CGM accuracy versus reference blood glucose in hospitalized T1D patients on HD</td></tr><tr><td rowspan="1" colspan="1">59.</td><td rowspan="1" colspan="1">Weber et al,<sup>
<xref rid="bibr77-19322968251353811" ref-type="bibr">77</xref>
</sup> Switzerland</td><td rowspan="1" colspan="1"><bold>Design:</bold> Non-randomized clinical trial<break/><bold>Follow-up</bold>: 14 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 15<break/><bold>Diabetes type</bold>: 8 unspecified diabetes<break/><bold>Age:</bold> 71 &#177; 11 years<break/><bold>Sex:</bold> 11 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To validate flash glucose monitoring as a convenient glucose monitoring option for people on HD with and without diabetes<break/><bold>Diabetes technology:</bold> FreeStyle Libre<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primar</bold>y: Mean flash glucose values<break/>Mean absolute relative difference</td></tr><tr><td rowspan="1" colspan="1">60.</td><td rowspan="1" colspan="1">Williams et al,<sup>
<xref rid="bibr78-19322968251353811" ref-type="bibr">78</xref>
</sup> UK</td><td rowspan="1" colspan="1"><bold>Design</bold>: Case-control study<break/><bold>Follow-up:</bold> 72 hours</td><td rowspan="1" colspan="1"><bold>Sample</bold>: 15 (9 automated PD [APD] and 6 continuous ambulatory PD [CAPD]) and 16 CKD-5 controls<break/><bold>Diabetes type:</bold> Not specified<break/><bold>Age</bold>: PD: 74 [69&#8211;79]; Controls: 65 [54&#8211;70.5]<break/><bold>Sex:</bold> 21 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To describe 24-hour glycemic profiles in people on PD without diabetes and compare them to non-dialysis CKD-5 controls.<break/><bold>Diabetes technology:</bold> FreeStyle Libre<break/><bold>Dialysis modality:</bold> PD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> 24-hour average glycemic profiles</td></tr><tr><td rowspan="1" colspan="1">61.</td><td rowspan="1" colspan="1">Yajima et al,<sup>
<xref rid="bibr79-19322968251353811" ref-type="bibr">79</xref>
</sup> Japan</td><td rowspan="1" colspan="1"><bold>Design</bold>: Pre-post study<break/><bold>Follow-up</bold>: 24 weeks</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 21<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 70.4 &#177; 8.0 years<break/><bold>Sex:</bold> 16 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention</bold>: To evaluate the efficacy and safety of adding teneligliptin to insulin therapy in people with T2D on HD<break/><bold>Diabetes technology</bold>: CGMS iPro2<break/><bold>Dialysis modality</bold>: HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Efficacy and safety of adding teneligliptin to insulin therapy</td></tr><tr><td rowspan="1" colspan="1">62.</td><td rowspan="1" colspan="1">Yajima et al,<sup>
<xref rid="bibr80-19322968251353811" ref-type="bibr">80</xref>
</sup> Japan</td><td rowspan="1" colspan="1"><bold>Design:</bold> Non-randomized trial<break/><bold>Follow-up</bold>: 4 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 31 (HD: &#8804;6 months [short HD group, N = 16] and &gt;6 months [long HD group, N = 15]).<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 70.8 &#177; 8.1<break/><bold>Sex</bold>: 24 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To evaluate the accuracy of serum albumin&#8211;adjusted glycated albumin and GA for assessing glycemic control in people with T2D on HD<break/><bold>Diabetes technology</bold>: CGMS iPro2<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Accuracy of adjusted GA and GA in evaluating glycemic control</td></tr><tr><td rowspan="1" colspan="1">63.</td><td rowspan="1" colspan="1">Yajima et al,<sup>
<xref rid="bibr81-19322968251353811" ref-type="bibr">81</xref>
</sup> Japan</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cohort study<break/><bold>Follow-up</bold>: 7 days</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 15<break/><bold>Diabetes type</bold>: T2D<break/><bold>Age:</bold> 72 (66&#8211;79) years<break/><bold>Sex:</bold> 13 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To evaluate the efficacy and safety of dulaglutide added to insulin therapy in T2D on HD.<break/><bold>Diabetes technology</bold>: CGM iPro2<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary</bold>: Efficacy and safety of adding dulaglutide to insulin therapy in type 2 diabetes on HD.</td></tr><tr><td rowspan="1" colspan="1">64.</td><td rowspan="1" colspan="1">Yajima et al,<sup>
<xref rid="bibr82-19322968251353811" ref-type="bibr">82</xref>
</sup> Japan</td><td rowspan="1" colspan="1"><bold>Design:</bold> Cross-sectional study<break/><bold>Follow-up:</bold> Not reported</td><td rowspan="1" colspan="1"><bold>Sample:</bold> 13<break/><bold>Diabetes type:</bold> T2D<break/><bold>Age:</bold> 63.5 &#177; 11.3<break/><bold>Sex:</bold> 11 Male</td><td rowspan="1" colspan="1"><bold>Purpose of intervention:</bold> To assess flash glucose monitoring and CGM accuracy versus capillary glucose in T2D on HD.<break/><bold>Diabetes technology</bold>: Flash glucose monitoring FreeStyle Libre Pro; CGM iPro2 and SMBG.<break/><bold>Dialysis modality:</bold> HD</td><td rowspan="1" colspan="1"><bold>Primary:</bold> Accuracy of flash glucose monitoring in people with T2D undergoing HD</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-19322968251353811"><p>Abbreviations: AID, automated insulin delivery; APD, automated peritoneal dialysis; AUC, area under the curve; CAPD, continuous ambulatory peritoneal dialysis; CGM, continuous glucose monitoring; CGMS, continuous glucose monitoring system; CKD-5, chronic kidney disease stage 5; CV, coefficient of variation; eHbA<sub>1c</sub>, Estimated HbA<sub>1c</sub>; GA, glycated albumin; GMI, glucose management indicator; HD, hemodialysis; MAGE, mean amplitude of glycemic excursions; MARD, mean absolute relative difference; PD, peritoneal dialysis; SD, standard deviation; SMBG, self-monitoring of blood glucose; T1D, type 1 diabetes; T2D, type 2 diabetes; TAR, time above range; TBR, time below range; TIR, time in range; YSI, Yellow Springs Instrument.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section22-19322968251353811"><title>Findings</title><p>The extracted data from the studies were categorized into six key themes: the validation of CGM accuracy in dialysis populations, comparisons between CGM and traditional glycemic markers, the impact of dialysis on glucose profiles, the use of CGM to assess the efficacy of diabetes treatments, CGM-based evaluations of glycemic outcomes, and the application of AID systems in the dialysis population. <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/19322968251353811" ext-link-type="uri">Tables 2</ext-link> to <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/19322968251353811" ext-link-type="uri">7 in Supplemental File 1</ext-link> provide an overview of the outcomes assessed in the included studies and show how each study contributed to these thematic categories.</p><sec id="section23-19322968251353811"><title>Validation studies: accuracy of CGM in dialysis populations</title><p>The 18 studies<sup><xref rid="bibr19-19322968251353811" ref-type="bibr">19</xref>,<xref rid="bibr31-19322968251353811" ref-type="bibr">31</xref>,<xref rid="bibr35-19322968251353811" ref-type="bibr">35</xref>,<xref rid="bibr36-19322968251353811" ref-type="bibr">36</xref>,<xref rid="bibr39-19322968251353811" ref-type="bibr">39</xref>,<xref rid="bibr43-19322968251353811" ref-type="bibr">43</xref>,<xref rid="bibr44-19322968251353811" ref-type="bibr">44</xref>,<xref rid="bibr48-19322968251353811" ref-type="bibr">48</xref>
<xref rid="bibr49-19322968251353811" ref-type="bibr"/><xref rid="bibr50-19322968251353811" ref-type="bibr"/>-<xref rid="bibr51-19322968251353811" ref-type="bibr">51</xref>,<xref rid="bibr59-19322968251353811" ref-type="bibr">59</xref>,<xref rid="bibr66-19322968251353811" ref-type="bibr">66</xref>,<xref rid="bibr71-19322968251353811" ref-type="bibr">71</xref>,<xref rid="bibr74-19322968251353811" ref-type="bibr">74</xref>,<xref rid="bibr76-19322968251353811" ref-type="bibr">76</xref>,<xref rid="bibr77-19322968251353811" ref-type="bibr">77</xref>,<xref rid="bibr82-19322968251353811" ref-type="bibr">82</xref></sup> reviewed included a total of 483 people undergoing dialysis, examining the accuracy and clinical utility of CGM and flash glucose monitoring devices in this population, with reference to capillary blood glucose or laboratory glucose measurements (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/19322968251353811" ext-link-type="uri">Table 2 in Supplemental File</ext-link>). Accuracy measures, such as the MARD, ranged from 8.1% to 29%,<sup><xref rid="bibr19-19322968251353811" ref-type="bibr">19</xref>,<xref rid="bibr31-19322968251353811" ref-type="bibr">31</xref>,<xref rid="bibr35-19322968251353811" ref-type="bibr">35</xref>,<xref rid="bibr48-19322968251353811" ref-type="bibr">48</xref>,<xref rid="bibr59-19322968251353811" ref-type="bibr">59</xref>,<xref rid="bibr71-19322968251353811" ref-type="bibr">71</xref>,<xref rid="bibr74-19322968251353811" ref-type="bibr">74</xref>,<xref rid="bibr76-19322968251353811" ref-type="bibr">76</xref>,<xref rid="bibr77-19322968251353811" ref-type="bibr">77</xref>,<xref rid="bibr82-19322968251353811" ref-type="bibr">82</xref></sup> with most studies reporting MARD values between 10% and 20%. Correlation coefficients between CGM/flash glucose monitoring readings and capillary or laboratory glucose were generally strong (r<sup>2</sup> ranging from 0.77 to 0.936). Accuracy was frequently reduced during or immediately after dialysis (<italic toggle="yes">P</italic> &lt; .05), with statistically significant differences observed between dialysis and non-dialysis days.<sup>
<xref rid="bibr71-19322968251353811" ref-type="bibr">71</xref>
</sup> Error grid analyses consistently showed that over 97% of glucose readings fell within clinically acceptable zones A and B, indicating good clinical reliability of these monitoring systems in dialysis population.<sup><xref rid="bibr19-19322968251353811" ref-type="bibr">19</xref>,<xref rid="bibr36-19322968251353811" ref-type="bibr">36</xref>,<xref rid="bibr49-19322968251353811" ref-type="bibr">49</xref>,<xref rid="bibr59-19322968251353811" ref-type="bibr">59</xref>,<xref rid="bibr74-19322968251353811" ref-type="bibr">74</xref>,<xref rid="bibr76-19322968251353811" ref-type="bibr">76</xref></sup></p></sec><sec id="section24-19322968251353811"><title>Comparisons between continuous glucose monitoring and traditional glycemic markers in dialysis populations</title><p>Thirteen studies<sup><xref rid="bibr21-19322968251353811" ref-type="bibr">21</xref>,<xref rid="bibr23-19322968251353811" ref-type="bibr">23</xref>,<xref rid="bibr29-19322968251353811" ref-type="bibr">29</xref>,<xref rid="bibr47-19322968251353811" ref-type="bibr">47</xref>,<xref rid="bibr53-19322968251353811" ref-type="bibr">53</xref>
<xref rid="bibr54-19322968251353811" ref-type="bibr"/>-<xref rid="bibr55-19322968251353811" ref-type="bibr">55</xref>,<xref rid="bibr60-19322968251353811" ref-type="bibr">60</xref>,<xref rid="bibr63-19322968251353811" ref-type="bibr">63</xref>,<xref rid="bibr64-19322968251353811" ref-type="bibr">64</xref>,<xref rid="bibr66-19322968251353811" ref-type="bibr">66</xref></sup>,<sup><xref rid="bibr73-19322968251353811" ref-type="bibr">73</xref>,<xref rid="bibr80-19322968251353811" ref-type="bibr">80</xref></sup> involving a total of approximately 397 people on dialysis, consistently show that HbA<sub>1c</sub> underestimates true glycemic level (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/19322968251353811" ext-link-type="uri">Table 3 in Supplemental File</ext-link>). Bomholt et al<sup>
<xref rid="bibr23-19322968251353811" ref-type="bibr">23</xref>
</sup> reported a mean underestimation of 7.3 mmol/mol (95% confidence interval [CI] = &#8211;10.0 to &#8211;4.7, <italic toggle="yes">P</italic> &lt; .001) in individuals on HD when comparing HbA<sub>1c</sub> with CGM. Similar findings were reported by Yajima et al,<sup>
<xref rid="bibr80-19322968251353811" ref-type="bibr">80</xref>
</sup> who observed a moderate correlation between HbA<sub>1c</sub> and CGM values (r = 0.508, <italic toggle="yes">P</italic> = .0037). The CGM also identified poor glycemic control more accurately than HbA<sub>1c</sub>, as shown by Divani et al<sup>
<xref rid="bibr29-19322968251353811" ref-type="bibr">29</xref>
</sup> (area under the curve [AUC] = 0.878 vs 0.682, <italic toggle="yes">P</italic> &lt; .01). Moderate correlations between HbA<sub>1c</sub> and CGM glucose levels have been observed in people on dialysis, as reported by Qayyum et al<sup>
<xref rid="bibr64-19322968251353811" ref-type="bibr">64</xref>
</sup> and Popa et al<sup>
<xref rid="bibr63-19322968251353811" ref-type="bibr">63</xref>
</sup> with the latter reporting a correlation of approximately r &#8776; 0.48 (<italic toggle="yes">P</italic> &lt; .0001). However, glycemic variability remains an issue. Factors such as body mass index and hemoglobin also contribute to discrepancies between HbA<sub>1c</sub> and glucose monitoring in this population.<sup>
<xref rid="bibr73-19322968251353811" ref-type="bibr">73</xref>
</sup></p></sec><sec id="section25-19322968251353811"><title>Impact of dialysis on glucose profiles</title><p>Four studies involving approximately 103 participants investigated the effects of dialysis on glucose profiles in people with diabetes using CGM (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/19322968251353811" ext-link-type="uri">Table 4 in Supplemental File</ext-link>).<sup><xref rid="bibr26-19322968251353811" ref-type="bibr">26</xref>,<xref rid="bibr61-19322968251353811" ref-type="bibr">61</xref>,<xref rid="bibr69-19322968251353811" ref-type="bibr">69</xref>,<xref rid="bibr70-19322968251353811" ref-type="bibr">70</xref></sup> Among those undergoing PD, individuals on automated peritoneal dialysis (APD) exhibited lower average blood glucose levels (181 &#177; 64 mg/dL) and less variability (SD = 36.3 &#177; 14.5 mg/dL) compared to those on continuous ambulatory peritoneal dialysis (CAPD), who recorded higher levels (238 &#177; 67 mg/dL; SD = 49.2 &#177; 14.1 mg/dL) (<italic toggle="yes">P</italic> &lt; .05).<sup>
<xref rid="bibr61-19322968251353811" ref-type="bibr">61</xref>
</sup> The use of high-glucose peritoneal fluids was associated with increased 24-hour glucose exposure, elevated peaks (up to 320 mg/dL), and more pronounced fluctuations, particularly among individuals with T1D (type 1 diabetes).<sup><xref rid="bibr69-19322968251353811" ref-type="bibr">69</xref>,<xref rid="bibr70-19322968251353811" ref-type="bibr">70</xref></sup> In HD, mean glucose levels were significantly lower during dialysis compared to post-dialysis (7.5 &#177; 2.5 vs 9.4 &#177; 1.9 mmol/L; <italic toggle="yes">P</italic> &lt; .001), with reduced variability but a higher frequency of hypoglycemia (4.4% vs 2.1%; <italic toggle="yes">P</italic> &lt; .001).<sup>
<xref rid="bibr26-19322968251353811" ref-type="bibr">26</xref>
</sup></p></sec><sec id="section26-19322968251353811"><title>Assessing the efficacy of diabetes treatments using continuous glucose monitoring</title><p>Eleven studies involving 257 participants with T2D (type 2 diabetes) on HD evaluated interventions including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (liraglutide, dulaglutide), dipeptidyl peptidase-4 (DPP-4) inhibitors (vildagliptin, teneligliptin), basal-bolus insulin, and basal insulin analogues (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/19322968251353811" ext-link-type="uri">Table 5 in Supplemental File</ext-link>).<sup><xref rid="bibr22-19322968251353811" ref-type="bibr">22</xref>,<xref rid="bibr32-19322968251353811" ref-type="bibr">32</xref>,<xref rid="bibr45-19322968251353811" ref-type="bibr">45</xref>,<xref rid="bibr57-19322968251353811" ref-type="bibr">57</xref>,<xref rid="bibr62-19322968251353811" ref-type="bibr">62</xref>,<xref rid="bibr65-19322968251353811" ref-type="bibr">65</xref>,<xref rid="bibr68-19322968251353811" ref-type="bibr">68</xref>,<xref rid="bibr72-19322968251353811" ref-type="bibr">72</xref>,<xref rid="bibr75-19322968251353811" ref-type="bibr">75</xref>,<xref rid="bibr79-19322968251353811" ref-type="bibr">79</xref>,<xref rid="bibr81-19322968251353811" ref-type="bibr">81</xref></sup> Bomholt et al<sup>
<xref rid="bibr22-19322968251353811" ref-type="bibr">22</xref>
</sup> reported a non-significant change with liraglutide (7.5-7.4%, <italic toggle="yes">P</italic> = .81), whereas G&#243;mez et al<sup>
<xref rid="bibr32-19322968251353811" ref-type="bibr">32</xref>
</sup> observed a significant reduction of &#8722;0.74% (<italic toggle="yes">P</italic> &lt; .0001). Similarly, K&#233;p&#233;n&#233;kian et al<sup>
<xref rid="bibr45-19322968251353811" ref-type="bibr">45</xref>
</sup> reported a decrease from 8.4% to 7.6% following CGM-guided adjustments (<italic toggle="yes">P</italic> &lt; .01), and Munch et al<sup>
<xref rid="bibr57-19322968251353811" ref-type="bibr">57</xref>
</sup> found a 0.6% reduction with vildagliptin plus insulin (<italic toggle="yes">P</italic> &lt; .01).</p><p>Improvements in glycemic variability were also reported. Yajima et al<sup>
<xref rid="bibr81-19322968251353811" ref-type="bibr">81</xref>
</sup> demonstrated a reduction in the coefficient of variation (CV) from 28.1% to 19.8% (<italic toggle="yes">P</italic> = .003), while Savu et al<sup>
<xref rid="bibr68-19322968251353811" ref-type="bibr">68</xref>
</sup> noted significant decreases on both HD and non-HD days (<italic toggle="yes">P</italic> = .0001 and <italic toggle="yes">P</italic> = .0011, respectively). Insulin requirements declined significantly in some studies. For instance, insulin doses were reduced from 18 to 6 units with teneligliptin (<italic toggle="yes">P</italic> &lt; .0001)<sup>
<xref rid="bibr79-19322968251353811" ref-type="bibr">79</xref>
</sup> and by 15 units per day with dulaglutide (<italic toggle="yes">P</italic> = .002).<sup>
<xref rid="bibr72-19322968251353811" ref-type="bibr">72</xref>
</sup> While liraglutide was associated with an increase in mild hypoglycemia (<italic toggle="yes">P</italic> = .02),<sup>
<xref rid="bibr22-19322968251353811" ref-type="bibr">22</xref>
</sup> most studies reported no significant rise in hypoglycemic episodes.</p></sec><sec id="section27-19322968251353811"><title>Continuous glucose monitoring-based evaluation of glycemic outcomes in the dialysis population</title><p>Twenty-two studies involving 768 people with diabetes on dialysis reported glycemic outcomes (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/19322968251353811" ext-link-type="uri">Table 6 in Supplemental File</ext-link>).<sup><xref rid="bibr24-19322968251353811" ref-type="bibr">24</xref>,<xref rid="bibr27-19322968251353811" ref-type="bibr">27</xref>,<xref rid="bibr30-19322968251353811" ref-type="bibr">30</xref>,<xref rid="bibr32-19322968251353811" ref-type="bibr">32</xref></sup>,<sup><xref rid="bibr33-19322968251353811" ref-type="bibr">33</xref>,<xref rid="bibr34-19322968251353811" ref-type="bibr">34</xref>,<xref rid="bibr37-19322968251353811" ref-type="bibr">37</xref>,<xref rid="bibr38-19322968251353811" ref-type="bibr">38</xref>,<xref rid="bibr40-19322968251353811" ref-type="bibr">40</xref>
<xref rid="bibr41-19322968251353811" ref-type="bibr"/>-<xref rid="bibr42-19322968251353811" ref-type="bibr">42</xref>,<xref rid="bibr46-19322968251353811" ref-type="bibr">46</xref>,<xref rid="bibr52-19322968251353811" ref-type="bibr">52</xref>,<xref rid="bibr54-19322968251353811" ref-type="bibr">54</xref></sup>-<sup><xref rid="bibr56-19322968251353811" ref-type="bibr">56</xref>,<xref rid="bibr58-19322968251353811" ref-type="bibr">58</xref>,<xref rid="bibr63-19322968251353811" ref-type="bibr">63</xref>,<xref rid="bibr65-19322968251353811" ref-type="bibr">65</xref>,<xref rid="bibr68-19322968251353811" ref-type="bibr">68</xref>,<xref rid="bibr78-19322968251353811" ref-type="bibr">78</xref></sup> Glucose levels typically fell during dialysis and rebounded afterwards, with notable nocturnal variation, eg, drop from 8.8 to 8.4 mmol/L (<italic toggle="yes">P</italic> = .029).<sup>
<xref rid="bibr24-19322968251353811" ref-type="bibr">24</xref>
</sup> The TIR was generally lower on dialysis days but improved following interventions, eg, Chantrel et al<sup>
<xref rid="bibr27-19322968251353811" ref-type="bibr">27</xref>
</sup> (TIR = 80.2%, <italic toggle="yes">P</italic> = .02) and Lee et al<sup>
<xref rid="bibr46-19322968251353811" ref-type="bibr">46</xref>
</sup> post-intervention improvement (<italic toggle="yes">P</italic> &lt; .05). Glycemic variability increased on dialysis days (<italic toggle="yes">P</italic> &lt; .05).<sup>
<xref rid="bibr54-19322968251353811" ref-type="bibr">54</xref>
</sup> Hypoglycemia risk varied: some studies showed no significant increase (<italic toggle="yes">P</italic> = .77),<sup>
<xref rid="bibr32-19322968251353811" ref-type="bibr">32</xref>
</sup> while others reported extended hyperglycemia mean Time Above Range (TAR) (49%) and Time Below Range (TBR) (2%).<sup>
<xref rid="bibr52-19322968251353811" ref-type="bibr">52</xref>
</sup> Educational and insulin adjustment programs reduced HbA<sub>1c</sub> by up to 0.74% (<italic toggle="yes">P</italic> &lt; .0001)<sup>
<xref rid="bibr32-19322968251353811" ref-type="bibr">32</xref>
</sup> and improved glycemic control.</p></sec><sec id="section28-19322968251353811"><title>Automated insulin delivery in the dialysis population</title><p>Four studies involving 48 participants with diabetes undergoing dialysis (T1D, T2D) evaluated the safety and efficacy of AID systems (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/19322968251353811" ext-link-type="uri">Table 7 in Supplemental File</ext-link>).<sup><xref rid="bibr20-19322968251353811" ref-type="bibr">20</xref>,<xref rid="bibr25-19322968251353811" ref-type="bibr">25</xref>,<xref rid="bibr28-19322968251353811" ref-type="bibr">28</xref>,<xref rid="bibr67-19322968251353811" ref-type="bibr">67</xref></sup> All studies reported significant improvements in glycemic levels, particularly in TIR. Bally et al<sup>
<xref rid="bibr20-19322968251353811" ref-type="bibr">20</xref>
</sup> found that users of closed-loop systems spent 69.0% of the time within the target range, compared with 31.5% in the control group, a difference of 37.6% (95% CI = 24.4-50.8; <italic toggle="yes">P</italic> &lt; .001). Boughton et al<sup>
<xref rid="bibr25-19322968251353811" ref-type="bibr">25</xref>
</sup> reported an increase in TIR from 37.7 to 52.8% (<italic toggle="yes">P</italic> &lt; .001), while Rossi et al<sup>
<xref rid="bibr67-19322968251353811" ref-type="bibr">67</xref>
</sup> observed a rise from 63% at baseline to 72% at three months and 74% at one year. Chaudhry et al<sup>
<xref rid="bibr28-19322968251353811" ref-type="bibr">28</xref>
</sup> recorded an increase from 43.5 to 64.8% (<italic toggle="yes">P</italic> = .015).</p><p>Mean glucose levels also declined. Boughton et al<sup>
<xref rid="bibr25-19322968251353811" ref-type="bibr">25</xref>
</sup> reported a reduction from 11.6 to 10.1 mmol/L (<italic toggle="yes">P</italic> = .003), while Chaudhry et al<sup>
<xref rid="bibr28-19322968251353811" ref-type="bibr">28</xref>
</sup> noted a non-significant drop of 2.13 mmol/L (<italic toggle="yes">P</italic> = .06). Bally et al<sup>
<xref rid="bibr20-19322968251353811" ref-type="bibr">20</xref>
</sup> found no increase in hypoglycemia with closed-loop use, whereas Boughton et al<sup>
<xref rid="bibr25-19322968251353811" ref-type="bibr">25</xref>
</sup> observed a significant reduction (0.1% vs 0.2%; <italic toggle="yes">P</italic> = .040).</p><p>Additional outcomes included lower glycemic variability; Rossi et al<sup>
<xref rid="bibr67-19322968251353811" ref-type="bibr">67</xref>
</sup> reported a reduction in the CV to 24% at one year and a decrease in HbA<sub>1c</sub> to 55 mmol/mol (7.2%). Chaudhry et al<sup>
<xref rid="bibr28-19322968251353811" ref-type="bibr">28</xref>
</sup> observed a significant decrease in TAR, from 55.5% to 34.8% (<italic toggle="yes">P</italic> = .03), although glycemic variability remained unchanged.</p></sec></sec></sec><sec sec-type="discussion" id="section29-19322968251353811"><title>Discussion</title><p>This review highlights the potential of CGM and AID technologies to enhance diabetes management in the dialysis population. Evidence from a range of studies underscores their effectiveness in addressing the distinct challenges associated with both HD and PD. Individuals receiving dialysis are particularly susceptible to hypoglycemia, hyperglycemia, and glycemic variability, largely due to dialysis-induced metabolic changes.</p><p>Validation studies included in the review confirm that CGM systems offer acceptable accuracy in both HD and PD settings, with MARD values typically between 10% and 23%. These results align with findings in non-dialysis populations<sup><xref rid="bibr83-19322968251353811" ref-type="bibr">83</xref>
<xref rid="bibr84-19322968251353811" ref-type="bibr"/><xref rid="bibr85-19322968251353811" ref-type="bibr"/><xref rid="bibr86-19322968251353811" ref-type="bibr"/><xref rid="bibr87-19322968251353811" ref-type="bibr"/>-<xref rid="bibr88-19322968251353811" ref-type="bibr">88</xref></sup> and show strong correlations with laboratory glucose and self-monitoring of blood glucose (SMBG), supporting CGM as a reliable monitoring tool for people on dialysis.<sup>
<xref rid="bibr89-19322968251353811" ref-type="bibr">89</xref>
</sup> However, accuracy often declines during and shortly after HD, likely due to physiological changes and sensor lag,<sup><xref rid="bibr90-19322968251353811" ref-type="bibr">90</xref>,<xref rid="bibr91-19322968251353811" ref-type="bibr">91</xref></sup> requiring cautious interpretation. Despite this, CGM provides valuable insights such as trend data and alarms. In contrast, SMBG, while accurate, provides only snapshot measurements and lacks the continuous glucose profile offered by CGM. Furthermore, Clarke and Parkes Consensus Error Grid analyses across the included studies demonstrated high clinical accuracy of CGM and flash glucose monitoring devices in dialysis populations. Specifically, 97%&#8211;99% of glucose readings fell within Zones A and B on the Clarke Error Grid, and 98%&#8211;100% on the Parkes Consensus Error Grid, indicating no or minimal clinical risk. These results are comparable to findings in non-dialysis populations, supporting the reliability of CGM in the dialysis setting.</p><p>Traditional markers such as HbA<sub>1c</sub> consistently underestimate glycemic levels in dialysis populations due to altered red blood cell lifespan, erythropoietin use, and the uremic environment. This review reaffirms that HbA<sub>1c</sub> is less reliable in this context. Glycated albumin shows stronger correlation with CGM-derived glucose values and provides a more accurate measure of glycemic control in people receiving dialysis,<sup>
<xref rid="bibr92-19322968251353811" ref-type="bibr">92</xref>
</sup> highlighting the need to consider alternative or additional markers. The TIR has been proposed as a complementary biomarker, offering several advantages over HbA<sub>1c</sub>. It reflects glycemic variability, captures hypoglycemia and hyperglycemia, responds quickly to treatment changes, and is not affected by pathological factors that may affect HbA<sub>1c</sub> levels.<sup>
<xref rid="bibr90-19322968251353811" ref-type="bibr">90</xref>
</sup></p><p>The dynamic impact of dialysis on glucose profiles was evident. Differences in glucose patterns between APD and CAPD modalities further illustrate the complexity of glycemic management in this population, particularly due to the sustained hyperglycemia associated with high-glucose dialysate solutions. Moreover, mean glucose levels were significantly lower during dialysis sessions and higher post-dialysis, accompanied by increased glucose variability and a higher incidence of hypoglycemia during dialysis. These glycemic fluctuations present a clinical challenge and underscore the value of CGM in providing real-time insights into glucose trends and enabling timely interventions.</p><p>Studies evaluating the use of CGM to guide diabetes treatment have demonstrated its effectiveness in monitoring therapeutic impact on glycemic control. These findings underscore the value of CGM in optimizing medication regimens for people on dialysis by enhancing efficacy and reducing the risk of hypoglycemia. Intervention studies further support the potential of CGM-guided adjustments to improve glycemic outcomes in this population. In non-dialysis populations, CGM is also a feasible tool for comparing treatment approaches.<sup>
<xref rid="bibr93-19322968251353811" ref-type="bibr">93</xref>
</sup> However, uncertainty regarding regulatory acceptance of CGM data may hinder wider adoption. Clear guidance from authorities such as the Conformit&#233; Europ&#233;enne (CE) and Food and Drug Administration (FDA) would help establish its role in the evaluation of new therapies.<sup>
<xref rid="bibr93-19322968251353811" ref-type="bibr">93</xref>
</sup></p><p>This review further highlights the utility of CGM in managing glycemia and glycemic variability in people on dialysis. The CGM effectively identifies intradialytic glucose lows and post-dialytic highs, supporting tailored insulin adjustments and improved glycemic level without increasing the risk of hypoglycemia. It also captures glycemic differences between dialysis and non-dialysis days, providing insights into metabolic fluctuations. These findings are supported by previous systematic reviews,<sup><xref rid="bibr15-19322968251353811" ref-type="bibr">15</xref>
<xref rid="bibr16-19322968251353811" ref-type="bibr"/>-<xref rid="bibr17-19322968251353811" ref-type="bibr">17</xref></sup>,<sup>
<xref rid="bibr94-19322968251353811" ref-type="bibr">94</xref>
</sup> further reinforcing the potential of CGM in this population.<sup>
<xref rid="bibr89-19322968251353811" ref-type="bibr">89</xref>
</sup></p><p>The AID systems have proven effective in non-dialysis populations, improving TIR, reducing hypoglycemia, and enhancing glycemic variability compared to standard insulin therapy.<sup><xref rid="bibr95-19322968251353811" ref-type="bibr">95</xref>,<xref rid="bibr96-19322968251353811" ref-type="bibr">96</xref></sup> Emerging evidence in dialysis people shows similar benefits despite metabolic fluctuations during HD or PD. Closed-loop insulin delivery offers a person-centered approach by lessening the need for frequent monitoring and insulin adjustments. However, altered insulin clearance, slow insulin pharmacokinetics, and potential CGM inaccuracies during dialysis present challenges.<sup>
<xref rid="bibr89-19322968251353811" ref-type="bibr">89</xref>
</sup> Still, studies in T1D and T2D people on dialysis report improved glucose control and safety with fully closed-loop systems. Although current data are limited, larger, longer-term trials are needed to confirm these benefits and support wider use in this complex group.</p><p>Despite growing evidence and endorsement from national and international guidelines supporting the use of diabetes technologies in dialysis settings,<sup><xref rid="bibr8-19322968251353811" ref-type="bibr">8</xref>,<xref rid="bibr97-19322968251353811" ref-type="bibr">97</xref></sup> their utilization remains limited in this vulnerable population. Historically, and in line with manufacturer guidance, the use of CGM devices (including Dexcom G5/G6/G7 and FreeStyle Libre 1/2/3) has not been recommended for people on dialysis due to limited accuracy data in this group. However, as the evidence base grows, manufacturers will need to reconsider their current guidance.</p><p>Laursen et al<sup>
<xref rid="bibr98-19322968251353811" ref-type="bibr">98</xref>
</sup> explored the experiences of people on HD using CGM, identifying six key themes: improved management of hypo- and hyperglycemia, informed decision-making, reduced practical challenges, enhanced confidence and safety, greater effectiveness with health care professional support, and mixed opinions on alarms. Overall, participants viewed CGM as a valuable tool for diabetes management during dialysis. However, additional health care professional support or tailored education may be needed to maximize CGM use and alleviate psychosocial challenges such as anxiety related to alarms or device burden, thereby enabling more sustained use.</p><p>Both CGM and AID offer significant benefits for glycemic management in this population. Yet, barriers including cost, limited clinical capacity, and workforce readiness continue to hinder routine integration.<sup>
<xref rid="bibr13-19322968251353811" ref-type="bibr">13</xref>
</sup> Persistent inequities in access further restrict utilization and limit optimization of diabetes care for those at greatest risk.<sup><xref rid="bibr89-19322968251353811" ref-type="bibr">89</xref>,<xref rid="bibr99-19322968251353811" ref-type="bibr">99</xref></sup> To overcome these challenges, targeted staff training, adequate funding, and clear care pathways are essential. These measures would support effective adoption, provide ongoing clinical support, and promote equitable access to diabetes technologies in dialysis settings. Further research on implementation strategies is needed to refine treatment approaches and improve care for people with diabetes undergoing dialysis. While CGM and AID systems show promise, their high costs, lack of universal reimbursement, and limited access, particularly in low- and middle-income countries, pose significant barriers. Given the complex medical needs of this population, it is essential to raise awareness and promote equitable access to these technologies wherever feasible.</p><sec id="section30-19322968251353811"><title>Strengths and Weaknesses</title><p>This review provides a comprehensive overview of the potential benefits of CGM and AID in dialysis populations, drawing on studies from various dialysis modalities. It offers valuable insights into efficacy, safety, and glycemic outcomes but is limited by small sample sizes, varying follow-up durations, and the inclusion of lower-level evidence such as cross-sectional analyses, audits, and case reports, which may affect consistency and weaken conclusions. While scoping reviews typically do not include formal quality appraisal, the predominance of observational data and variability in study quality should be considered when interpreting the findings. Most studies were conducted in Europe, Asia, and the Americas, with limited representation from low- and middle-income countries, potentially restricting the generalizability of the results.</p></sec></sec><sec sec-type="conclusions" id="section31-19322968251353811"><title>Conclusion</title><p>This review highlights the promising role of CGM and AID in improving diabetes management in dialysis populations. The CGM reliably monitors glucose, offering valuable insights to guide treatment, while AID improves glucose level and safety with a personalized approach. Integrating these technologies into routine care could enhance outcomes and reduce diabetes burden in people on dialysis. Wider adoption requires clear clinical pathways, dedicated funding, and health care professional training. Further research is needed to optimize implementation and ensure optimal care.</p></sec><sec sec-type="supplementary-material" id="section32-19322968251353811" specific-use="figshare"><title>Supplemental Material</title><supplementary-material id="suppl1-19322968251353811" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-docx-1-dst-10.1177_19322968251353811 &#8211; Supplemental material for Scoping Review&#8212;Diabetes Technology for Individuals on Kidney Replacement Therapy (Dialysis): Current Trends and Future Directions</title></caption><media xlink:href="sj-docx-1-dst-10.1177_19322968251353811.docx" position="float" orientation="portrait"/><p>Supplemental material, sj-docx-1-dst-10.1177_19322968251353811 for Scoping Review&#8212;Diabetes Technology for Individuals on Kidney Replacement Therapy (Dialysis): Current Trends and Future Directions by Hellena Hailu Habte-Asres, Joseph Ngmenesegre Suglo, Khuram Chaudhry, Angus Forbes, David C. Wheeler and Janaka Karalliedde in Journal of Diabetes Science and Technology</p></supplementary-material></sec></body><back><ack><p>Nil.</p></ack><fn-group><fn fn-type="other"><p><bold>Abbreviations:</bold> AID, automated insulin delivery; APD, automated peritoneal dialysis; AUC, area under the curve; CAPD, continuous ambulatory peritoneal dialysis; CE, Conformit&#233; Europ&#233;enne; CGM, continuous glucose monitoring; CINAHL, Cumulative Index to Nursing and Allied Health Literature; CSII, continuous subcutaneous insulin infusion; CV, coefficient of variation; DPP-4 inhibitors, dipeptidyl peptidase-4 inhibitors; ESKD, end-stage kidney disease; FDA, Food and Drug Administration; GLP-1 RA, Glucagon-Like Peptide-1 Receptor Agonists; HbA<sub>1c</sub>, glycated hemoglobin; HD, hemodialysis; KRT, kidney replacement therapy; MARD, mean absolute relative difference; MeSH, medical subject headings; mg/dL, milligrams per deciliter; PD, peritoneal dialysis; PRISMA, preferred reporting items for systematic reviews and meta-analyses; SD, standard deviation; SMBG, self-monitoring of blood glucose; T1D, type 1 diabetes; T2D, type 2 diabetes; TAR, time above range; TBR, time below range; TIR, time in range.</p></fn><fn fn-type="COI-statement"><p>The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: HHH-A received speaker honoraria from AstraZeneca and Bayer. JNS, KC, and AF have declared no conflicts of interest. DCW has an ongoing consultancy contract with AstraZeneca and has received payments for consultancy and/or speaking activities from multiple companies, including Amgen, Astellas, Bayer, Boehringer Ingelheim, Eledon, GSK, Galderma, Gilead, Janssen, Mundipharma, Menarini, MSD, NovoNordisk, Pharmacosmos, Tricida, and Vifor. JK has received honoraria for delivering educational meetings and/or attending advisory boards from Boehringer Ingelheim, AstraZeneca, Sanofi, and NAPP and research grants from AstraZeneca and Sanofi.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) received no financial support for the research, authorship, and/or publication of this article.</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Hellena Hailu Habte-Asres <inline-graphic xlink:href="10.1177_19322968251353811-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0001-8141-1423" ext-link-type="uri">https://orcid.org/0000-0001-8141-1423</ext-link></p></fn><fn fn-type="supplementary-material"><p><bold>Supplemental Material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-19322968251353811"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tye</surname><given-names>SC</given-names></name><name name-style="western"><surname>Denig</surname><given-names>P</given-names></name><name name-style="western"><surname>Heerspink</surname><given-names>HJL</given-names></name></person-group>. <article-title>Precision medicine approaches for diabetic kidney disease: opportunities and challenges</article-title>. <source>Nephrol Dial Transplant</source>. <year>2021</year>;<volume>36</volume>(<issue>suppl 2</issue>):ii3-ii9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfab045</pub-id><pub-id pub-id-type="pmcid">PMC8216727</pub-id><pub-id pub-id-type="pmid">34153985</pub-id></mixed-citation></ref><ref id="bibr2-19322968251353811"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abe</surname><given-names>M</given-names></name><name name-style="western"><surname>Kalantar-Zadeh</surname><given-names>K.</given-names></name></person-group><article-title>Haemodialysis-induced hypoglycaemia and glycaemic disarrays</article-title>. <source>Nat Rev Nephrol</source>. <year>2015</year>;<volume>11</volume>(<issue>5</issue>):<fpage>302</fpage>-<lpage>313</lpage>.<pub-id pub-id-type="pmid">25848881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneph.2015.38</pub-id><pub-id pub-id-type="pmcid">PMC6015632</pub-id></mixed-citation></ref><ref id="bibr3-19322968251353811"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wijewickrama</surname><given-names>P</given-names></name><name name-style="western"><surname>Onyema</surname><given-names>M</given-names></name><name name-style="western"><surname>Eid</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>. <article-title>Standards of diabetes care and burden of hypoglycaemia in people with diabetes on peritoneal dialysis: results from a real-world clinical audit</article-title>. <source>Perit Dial Int</source>. <year>2024</year>;<volume>44</volume>:<fpage>216</fpage>-<lpage>220</lpage>.<pub-id pub-id-type="pmid">37702352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/08968608231195492</pub-id></mixed-citation></ref><ref id="bibr4-19322968251353811"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galindo</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Ali</surname><given-names>MK</given-names></name><name name-style="western"><surname>Funni</surname><given-names>SA</given-names></name></person-group>, <etal>et al</etal>. <article-title>Hypoglycemic and hyperglycemic crises among U.S. adults with diabetes and end-stage kidney disease: population-based study, 2013-2017</article-title>. <source>Diabetes Care</source>. <year>2022</year>;<volume>45</volume>(<issue>1</issue>):<fpage>100</fpage>-<lpage>107</lpage>.<pub-id pub-id-type="pmid">34740910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc21-1579</pub-id><pub-id pub-id-type="pmcid">PMC8753755</pub-id></mixed-citation></ref><ref id="bibr5-19322968251353811"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eldehni</surname><given-names>MT</given-names></name><name name-style="western"><surname>Crowley</surname><given-names>LE</given-names></name><name name-style="western"><surname>Selby</surname><given-names>NM.</given-names></name></person-group><article-title>Challenges in management of diabetic patient on dialysis</article-title>. <source>Kidney Dial</source>. <year>2022</year>;<volume>2</volume>(<issue>4</issue>):<fpage>553</fpage>-<lpage>564</lpage>.</mixed-citation></ref><ref id="bibr6-19322968251353811"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habte-Asres</surname><given-names>HH</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Burden of impaired awareness of hypoglycemia in people with diabetes undergoing hemodialysis</article-title>. <source>BMJ Open Diabetes Res Care</source>. <year>2024</year>;<volume>12</volume>(<issue>1</issue>):e003730.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjdrc-2023-003730</pub-id><pub-id pub-id-type="pmcid">PMC10836342</pub-id><pub-id pub-id-type="pmid">38302432</pub-id></mixed-citation></ref><ref id="bibr7-19322968251353811"><label>7</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Haboosh</surname><given-names>S</given-names></name><name name-style="western"><surname>Eid</surname><given-names>H</given-names></name><name name-style="western"><surname>Onyema</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Burden of hypoglycaemia in people with diabetes on peritoneal dialysis</article-title>. <conf-name>Paper presented at ABCD Conference 2022</conf-name>; <conf-date>September 2022</conf-date>; <conf-loc>Birmingham</conf-loc>.</mixed-citation></ref><ref id="bibr8-19322968251353811"><label>8</label><mixed-citation publication-type="book"><collab>Joint British Diabetes Societies for Inpatient Care(JBDS-IP)</collab>. <source>Management of Adults With Diabetes on Dialysis</source>. <publisher-loc>London</publisher-loc>: <publisher-name>JBDS</publisher-name>; <year>2023</year>.</mixed-citation></ref><ref id="bibr9-19322968251353811"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>JC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P</given-names></name><name name-style="western"><surname>Ierino</surname><given-names>F</given-names></name><name name-style="western"><surname>MacIsaac</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Ekinci</surname><given-names>E</given-names></name><name name-style="western"><surname>O&#8217;Neal</surname><given-names>D.</given-names></name></person-group><article-title>Challenges of glycemic control in people with diabetes and advanced kidney disease and the potential of automated insulin delivery</article-title>. <source>J Diabetes Sci Technol</source>. <year>2024</year>;<volume>18</volume>(<issue>6</issue>):<fpage>1500</fpage>-<lpage>1508</lpage>.<pub-id pub-id-type="pmid">37162092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/19322968231174040</pub-id><pub-id pub-id-type="pmcid">PMC11531035</pub-id></mixed-citation></ref><ref id="bibr10-19322968251353811"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davenport</surname><given-names>A.</given-names></name></person-group><article-title>Interdialytic weight gain in diabetic haemodialysis patients and diabetic control as assessed by glycated haemoglobin</article-title>. <source>Nephron Clin Pract</source>. <year>2009</year>;<volume>113</volume>(<issue>1</issue>):c33-c37.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000228073</pub-id><pub-id pub-id-type="pmid">19590233</pub-id></mixed-citation></ref><ref id="bibr11-19322968251353811"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ifudu</surname><given-names>O</given-names></name><name name-style="western"><surname>Dulin</surname><given-names>AL</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>EA.</given-names></name></person-group><article-title>Interdialytic weight gain correlates with glycosylated hemoglobin in diabetic hemodialysis patients</article-title>. <source>Am J Kidney Dis</source>. <year>1994</year>;<volume>23</volume>(<issue>5</issue>):<fpage>686</fpage>-<lpage>691</lpage>.<pub-id pub-id-type="pmid">8172211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0272-6386(12)70279-2</pub-id></mixed-citation></ref><ref id="bibr12-19322968251353811"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>SC</given-names></name><name name-style="western"><surname>Guo</surname><given-names>HR</given-names></name></person-group>, <etal>et al</etal>. <article-title>The role of oral dryness in interdialytic weight gain by diabetic and non-diabetic haemodialysis patients</article-title>. <source>Nephrol Dial Transplant</source>. <year>2006</year>;<volume>21</volume>(<issue>9</issue>):<fpage>2521</fpage>-<lpage>2528</lpage>.<pub-id pub-id-type="pmid">16720594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfl236</pub-id></mixed-citation></ref><ref id="bibr13-19322968251353811"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habte-Asres</surname><given-names>HH</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>M</given-names></name><name name-style="western"><surname>Nitsch</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>. <article-title>Closing the policy gap in diabetes care for individuals with advanced CKD</article-title>. <source>Diabet Med</source>. <year>2024</year>;<volume>42</volume>:e15381.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dme.15381</pub-id><pub-id pub-id-type="pmcid">PMC11733654</pub-id><pub-id pub-id-type="pmid">38859547</pub-id></mixed-citation></ref><ref id="bibr14-19322968251353811"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habte-Asres</surname><given-names>HH</given-names></name><name name-style="western"><surname>Hou</surname><given-names>C</given-names></name><name name-style="western"><surname>Forbes</surname><given-names>A</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>DC.</given-names></name></person-group><article-title>Organisational initiatives to improve care in the prevention and management of cardiometabolic conditions: a scoping review</article-title>. <source>Nutr Metab Cardiovasc Dis</source>. <year>2024</year>;<volume>34</volume>(<issue>12</issue>):<fpage>2630</fpage>-<lpage>2641</lpage>.<pub-id pub-id-type="pmid">39438229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.numecd.2024.09.004</pub-id></mixed-citation></ref><ref id="bibr15-19322968251353811"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakubowska</surname><given-names>Z</given-names></name><name name-style="western"><surname>Malyszko</surname><given-names>J.</given-names></name></person-group><article-title>Continuous glucose monitoring in people with diabetes and end-stage kidney disease-review of association studies and evidence-based discussion</article-title>. <source>J Nephrol</source>. <year>2024</year>;<volume>37</volume>(<issue>2</issue>):<fpage>267</fpage>-<lpage>279</lpage>.<pub-id pub-id-type="pmid">37989976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40620-023-01802-w</pub-id><pub-id pub-id-type="pmcid">PMC11043101</pub-id></mixed-citation></ref><ref id="bibr16-19322968251353811"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallieni</surname><given-names>M</given-names></name><name name-style="western"><surname>De Salvo</surname><given-names>C</given-names></name><name name-style="western"><surname>Lunati</surname><given-names>ME</given-names></name></person-group>, <etal>et al</etal>. <article-title>Continuous glucose monitoring in patients with type 2 diabetes on hemodialysis</article-title>. <source>Acta Diabetol</source>. <year>2021</year>;<volume>58</volume>(<issue>8</issue>):<fpage>975</fpage>-<lpage>981</lpage>.<pub-id pub-id-type="pmid">33743082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00592-021-01699-6</pub-id><pub-id pub-id-type="pmcid">PMC8272699</pub-id></mixed-citation></ref><ref id="bibr17-19322968251353811"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P</given-names></name><name name-style="western"><surname>Ganapathy</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>. <article-title>Efficacy of continuous glucose monitoring in people living with diabetes and end stage kidney disease on dialysis: a systematic review</article-title>. <source>BMC Nephrol</source>. <year>2024</year>;<volume>25</volume>(<issue>1</issue>):<fpage>379</fpage>.<pub-id pub-id-type="pmid">39455937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12882-024-03763-z</pub-id><pub-id pub-id-type="pmcid">PMC11515242</pub-id></mixed-citation></ref><ref id="bibr18-19322968251353811"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>MDJ</given-names></name><name name-style="western"><surname>Marnie</surname><given-names>C</given-names></name><name name-style="western"><surname>Colquhoun</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>. <article-title>Scoping reviews: reinforcing and advancing the methodology and application</article-title>. <source>Syst Rev</source>. <year>2021</year>;<volume>10</volume>(<issue>1</issue>):<fpage>263</fpage>.<pub-id pub-id-type="pmid">34625095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13643-021-01821-3</pub-id><pub-id pub-id-type="pmcid">PMC8499488</pub-id></mixed-citation></ref><ref id="bibr19-19322968251353811"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avari</surname><given-names>P</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name><name name-style="western"><surname>Jugnee</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>. <article-title>The accuracy of continuous glucose sensors in people with diabetes undergoing hemodialysis (ALPHA study)</article-title>. <source>Diabetes Technol Ther</source>. <year>2023</year>;<volume>25</volume>(<issue>7</issue>):<fpage>447</fpage>-<lpage>456</lpage>.<pub-id pub-id-type="pmid">36961385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/dia.2023.0013</pub-id></mixed-citation></ref><ref id="bibr20-19322968251353811"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bally</surname><given-names>L</given-names></name><name name-style="western"><surname>Gubler</surname><given-names>P</given-names></name><name name-style="western"><surname>Thabit</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>. <article-title>Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis</article-title>. <source>Kidney Int</source>. <year>2019</year>;<volume>96</volume>(<issue>3</issue>):<fpage>593</fpage>-<lpage>596</lpage>.<pub-id pub-id-type="pmid">31133457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2019.03.006</pub-id></mixed-citation></ref><ref id="bibr21-19322968251353811"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bomholt</surname><given-names>T</given-names></name><name name-style="western"><surname>Feldt-Rasmussen</surname><given-names>B</given-names></name><name name-style="western"><surname>Butt</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>. <article-title>Hemoglobin A1c and fructosamine evaluated in patients with type 2 diabetes receiving peritoneal dialysis using long-term continuous glucose monitoring</article-title>. <source>Nephron</source>. <year>2021</year>;<volume>146</volume>(<issue>2</issue>):<fpage>146</fpage>-<lpage>152</lpage>.<pub-id pub-id-type="pmid">34731864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000519493</pub-id></mixed-citation></ref><ref id="bibr22-19322968251353811"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bomholt</surname><given-names>T</given-names></name><name name-style="western"><surname>Idorn</surname><given-names>T</given-names></name><name name-style="western"><surname>Knop</surname><given-names>FK</given-names></name></person-group>, <etal>et al</etal>. <article-title>The glycemic effect of liraglutide evaluated by continuous glucose monitoring in persons with type 2 diabetes receiving dialysis</article-title>. <source>Nephron</source>. <year>2021</year>;<volume>145</volume>(<issue>1</issue>):<fpage>27</fpage>-<lpage>34</lpage>.<pub-id pub-id-type="pmid">33105146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000510613</pub-id></mixed-citation></ref><ref id="bibr23-19322968251353811"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bomholt</surname><given-names>T</given-names></name><name name-style="western"><surname>Rix</surname><given-names>M</given-names></name><name name-style="western"><surname>Almdal</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>. <article-title>The accuracy of hemoglobin a1c and fructosamine evaluated by long-term continuous glucose monitoring in patients with type 2 diabetes undergoing hemodialysis</article-title>. <source>Blood Purif</source>. <year>2022</year>;<volume>51</volume>(<issue>7</issue>):<fpage>608</fpage>-<lpage>616</lpage>.<pub-id pub-id-type="pmid">34583354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000519050</pub-id></mixed-citation></ref><ref id="bibr24-19322968251353811"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bomholt</surname><given-names>T</given-names></name><name name-style="western"><surname>Rix</surname><given-names>M</given-names></name><name name-style="western"><surname>Almdal</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>. <article-title>Glucose variability in maintenance hemodialysis patients with type 2 diabetes: comparison of dialysis and nondialysis days</article-title>. <source>Hemodial Int</source>. <year>2023</year>;<volume>27</volume>(<issue>2</issue>):<fpage>126</fpage>-<lpage>133</lpage>.<pub-id pub-id-type="pmid">36760179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/hdi.13073</pub-id></mixed-citation></ref><ref id="bibr25-19322968251353811"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boughton</surname><given-names>CK</given-names></name><name name-style="western"><surname>Tripyla</surname><given-names>A</given-names></name><name name-style="western"><surname>Hartnell</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. <article-title>Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial</article-title>. <source>Nat Med</source>. <year>2021</year>;<volume>27</volume>(<issue>8</issue>):<fpage>1471</fpage>-<lpage>1476</lpage>.<pub-id pub-id-type="pmid">34349267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01453-z</pub-id><pub-id pub-id-type="pmcid">PMC8363503</pub-id></mixed-citation></ref><ref id="bibr26-19322968251353811"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chantrel</surname><given-names>F</given-names></name><name name-style="western"><surname>Sissoko</surname><given-names>H</given-names></name><name name-style="western"><surname>K&#233;p&#233;n&#233;kian</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>. <article-title>Influence of dialysis on the glucose profile in patients with diabetes: usefulness of continuous glucose monitoring</article-title>. <source>Horm Metab Res</source>. <year>2014</year>;<volume>46</volume>(<issue>11</issue>):<fpage>810</fpage>-<lpage>813</lpage>.<pub-id pub-id-type="pmid">24627097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0034-1370963</pub-id></mixed-citation></ref><ref id="bibr27-19322968251353811"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chantrel</surname><given-names>F</given-names></name><name name-style="western"><surname>Brockhes</surname><given-names>S</given-names></name><name name-style="western"><surname>Mountassir</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>. <article-title>Diabetes care in hemodialysis patients: advances made in 2020</article-title>. <source>Kidney Int Rep</source>. <year>2021</year>;<volume>6</volume>(<issue>4 suppl</issue>):S153-S154.</mixed-citation></ref><ref id="bibr28-19322968251353811"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhry</surname><given-names>K</given-names></name><name name-style="western"><surname>Hyslop</surname><given-names>R</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>T</given-names></name><name name-style="western"><surname>Pender</surname><given-names>S</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>S</given-names></name><name name-style="western"><surname>Karalliedde</surname><given-names>J.</given-names></name></person-group><article-title>Case series of using automated insulin delivery to improve glycaemic control in people with type 1 diabetes and end stage kidney disease on haemodialysis</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2024</year>;<volume>217</volume>:<fpage>111800</fpage>.<pub-id pub-id-type="pmid">39151730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2024.111800</pub-id></mixed-citation></ref><ref id="bibr29-19322968251353811"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Divani</surname><given-names>M</given-names></name><name name-style="western"><surname>Georgianos</surname><given-names>P</given-names></name><name name-style="western"><surname>Liakopoulos</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal>. <article-title>Evaluation of glycemic control and interday glucose variability using continuous glucose monitoring in diabetic hemodialysis patients</article-title>. <source>Nephrol Dial Transplant</source>. <year>2022</year>;<volume>37</volume>(<issue>suppl 3</issue>):gfac076.032.</mixed-citation></ref><ref id="bibr30-19322968251353811"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gai</surname><given-names>M</given-names></name><name name-style="western"><surname>Merlo</surname><given-names>I</given-names></name><name name-style="western"><surname>Dellepiane</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. <article-title>Glycemic pattern in diabetic patients on hemodialysis: continuous glucose monitoring (CGM) analysis</article-title>. <source>Blood Purif</source>. <year>2014</year>;<volume>38</volume>(<issue>1</issue>):<fpage>68</fpage>-<lpage>73</lpage>.<pub-id pub-id-type="pmid">25300368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000362863</pub-id></mixed-citation></ref><ref id="bibr31-19322968251353811"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Genua</surname><given-names>I</given-names></name><name name-style="western"><surname>S&#225;nchez-Hernandez</surname><given-names>J</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>MJ</given-names></name></person-group>, <etal>et al</etal>. <article-title>Accuracy of flash glucose monitoring in patients with diabetes mellitus on hemodialysis and its relationship with hydration status</article-title>. <source>J Diabetes Sci Technol</source>. <year>2021</year>;<volume>15</volume>(<issue>6</issue>):<fpage>1308</fpage>-<lpage>1312</lpage>.<pub-id pub-id-type="pmid">33251824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1932296820975057</pub-id><pub-id pub-id-type="pmcid">PMC8655287</pub-id></mixed-citation></ref><ref id="bibr32-19322968251353811"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez</surname><given-names>AM</given-names></name><name name-style="western"><surname>Vallejo</surname><given-names>S</given-names></name><name name-style="western"><surname>Ardila</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal>. <article-title>Impact of a basal-bolus insulin regimen on metabolic control and risk of hypoglycemia in patients with diabetes undergoing peritoneal dialysis</article-title>. <source>J Diabetes Sci Technol</source>. <year>2018</year>;<volume>12</volume>(<issue>1</issue>):<fpage>129</fpage>-<lpage>135</lpage>.<pub-id pub-id-type="pmid">28927285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1932296817730376</pub-id><pub-id pub-id-type="pmcid">PMC5761986</pub-id></mixed-citation></ref><ref id="bibr33-19322968251353811"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayashi</surname><given-names>A</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>N</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <article-title>Hemodialysis-related glycemic disarray proven by continuous glucose monitoring; glycemic markers and hypoglycemia</article-title>. <source>Diabetes Care</source>. <year>2021</year>;<volume>44</volume>(<issue>7</issue>):<fpage>1647</fpage>-<lpage>1656</lpage>.<pub-id pub-id-type="pmid">34045240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc21-0269</pub-id></mixed-citation></ref><ref id="bibr34-19322968251353811"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayashi</surname><given-names>A</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>N</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <article-title>Novel clinical associations between time in range and microangiopathies in people with type 2 diabetes mellitus on hemodialysis</article-title>. <source>J Diabetes Complications</source>. <year>2023</year>;<volume>37</volume>(<issue>5</issue>):<fpage>108470</fpage>.<pub-id pub-id-type="pmid">37043984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdiacomp.2023.108470</pub-id></mixed-citation></ref><ref id="bibr35-19322968251353811"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hissa</surname><given-names>MRN</given-names></name><name name-style="western"><surname>Hissa</surname><given-names>PNG</given-names></name><name name-style="western"><surname>Guimar&#227;es</surname><given-names>SB</given-names></name></person-group>, <etal>et al</etal>. <article-title>Use of continuous glucose monitoring system in patients with type 2 mellitus diabetic during hemodialysis treatment</article-title>. <source>Diabetol Metab Syndr</source>. <year>2021</year>;<volume>13</volume>(<issue>1</issue>):<fpage>104</fpage>.<pub-id pub-id-type="pmid">34625090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13098-021-00722-8</pub-id><pub-id pub-id-type="pmcid">PMC8501745</pub-id></mixed-citation></ref><ref id="bibr36-19322968251353811"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horne</surname><given-names>C</given-names></name><name name-style="western"><surname>Cranston</surname><given-names>I</given-names></name><name name-style="western"><surname>Amos</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Accuracy of continuous glucose monitoring in an insulin-treated population requiring haemodialysis</article-title>. <source>J Diabetes Sci Technol</source>. <year>2023</year>;<volume>17</volume>(<issue>4</issue>):<fpage>971</fpage>-<lpage>975</lpage>.<pub-id pub-id-type="pmid">37148160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/19322968231173447</pub-id><pub-id pub-id-type="pmcid">PMC10347996</pub-id></mixed-citation></ref><ref id="bibr37-19322968251353811"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>K</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>. <article-title>Analysis of glycemic improvement in hemodialysis patients based on time in range, assessed by flash glucose monitoring</article-title>. <source>Blood Purif</source>. <year>2021</year>;<volume>50</volume>(<issue>6</issue>):<fpage>883</fpage>-<lpage>890</lpage>.<pub-id pub-id-type="pmid">33774625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000513162</pub-id></mixed-citation></ref><ref id="bibr38-19322968251353811"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Javherani</surname><given-names>RS</given-names></name><name name-style="western"><surname>Purandare</surname><given-names>VB</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>AA</given-names></name><name name-style="western"><surname>Kumaran</surname><given-names>SS</given-names></name><name name-style="western"><surname>Sayyad</surname><given-names>MG</given-names></name><name name-style="western"><surname>Unnikrishnan</surname><given-names>AG.</given-names></name></person-group><article-title>Flash glucose monitoring in subjects with diabetes on hemodialysis: a pilot study</article-title>. <source>Indian J Endocrinol Metab</source>. <year>2018</year>;<volume>22</volume>(<issue>6</issue>):<fpage>848</fpage>-<lpage>851</lpage>.<pub-id pub-id-type="pmid">30766829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijem.IJEM_520_18</pub-id><pub-id pub-id-type="pmcid">PMC6330844</pub-id></mixed-citation></ref><ref id="bibr39-19322968251353811"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>YP</given-names></name><name name-style="western"><surname>Su</surname><given-names>XF</given-names></name><name name-style="western"><surname>Yin</surname><given-names>GP</given-names></name></person-group>, <etal>et al</etal>. <article-title>Blood glucose fluctuations in hemodialysis patients with end stage diabetic nephropathy</article-title>. <source>J Diabetes Complications</source>. <year>2015</year>;<volume>29</volume>(<issue>3</issue>):<fpage>395</fpage>-<lpage>399</lpage>.<pub-id pub-id-type="pmid">25681043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdiacomp.2014.12.015</pub-id></mixed-citation></ref><ref id="bibr40-19322968251353811"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joubert</surname><given-names>M</given-names></name><name name-style="western"><surname>Fourmy</surname><given-names>C</given-names></name><name name-style="western"><surname>Henri</surname><given-names>P</given-names></name><name name-style="western"><surname>Ficheux</surname><given-names>M</given-names></name><name name-style="western"><surname>Lobbedez</surname><given-names>T</given-names></name><name name-style="western"><surname>Reznik</surname><given-names>Y.</given-names></name></person-group><article-title>Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2015</year>;<volume>107</volume>(<issue>3</issue>):<fpage>348</fpage>-<lpage>354</lpage>.<pub-id pub-id-type="pmid">25638452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2015.01.026</pub-id></mixed-citation></ref><ref id="bibr41-19322968251353811"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>HS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HI</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MJ</given-names></name></person-group>, <etal>et al</etal>. <article-title>Analysis of hemodialysis-associated hypoglycemia in patients with type 2 diabetes using a continuous glucose monitoring system</article-title>. <source>Diabetes Technol Ther</source>. <year>2010</year>;<volume>12</volume>(<issue>10</issue>):<fpage>801</fpage>-<lpage>807</lpage>.<pub-id pub-id-type="pmid">20809681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/dia.2010.0067</pub-id></mixed-citation></ref><ref id="bibr42-19322968251353811"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaminski</surname><given-names>CY</given-names></name><name name-style="western"><surname>Galindo</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Navarrete</surname><given-names>JE</given-names></name></person-group>, <etal>et al</etal>. <article-title>Assessment of glycemic control by continuous glucose monitoring, hemoglobin A1c, fructosamine, and glycated albumin in patients with end-stage kidney disease and burnt-out diabetes</article-title>. <source>Diabetes Care</source>. <year>2024</year>;<volume>47</volume>(<issue>2</issue>):<fpage>267</fpage>-<lpage>271</lpage>.<pub-id pub-id-type="pmid">38085705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc23-1276</pub-id><pub-id pub-id-type="pmcid">PMC11148628</pub-id></mixed-citation></ref><ref id="bibr43-19322968251353811"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashem</surname><given-names>T</given-names></name><name name-style="western"><surname>Begum</surname><given-names>NAS</given-names></name><name name-style="western"><surname>Fan</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. <article-title>Sat-062 validating continuous glucose monitoring system in haemodialysis patients</article-title>. <source>Kidney Int Rep</source>. <year>2019</year>;<volume>4</volume>(<issue>7</issue>):S29.</mixed-citation></ref><ref id="bibr44-19322968251353811"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kazempour-Ardebili</surname><given-names>S</given-names></name><name name-style="western"><surname>Lecamwasam</surname><given-names>VL</given-names></name><name name-style="western"><surname>Dassanyake</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>. <article-title>Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2009</year>;<volume>32</volume>(<issue>7</issue>):<fpage>1137</fpage>-<lpage>1142</lpage>.<pub-id pub-id-type="pmid">19196889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc08-1688</pub-id><pub-id pub-id-type="pmcid">PMC2699727</pub-id></mixed-citation></ref><ref id="bibr45-19322968251353811"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#233;p&#233;n&#233;kian</surname><given-names>L</given-names></name><name name-style="western"><surname>Smagala</surname><given-names>A</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>. <article-title>Continuous glucose monitoring in hemodialyzed patients with type 2 diabetes: a multicenter pilot study</article-title>. <source>Clin Nephrol</source>. <year>2014</year>;<volume>82</volume>(<issue>4</issue>):<fpage>240</fpage>-<lpage>246</lpage>.<pub-id pub-id-type="pmid">25161114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5414/CN108280</pub-id></mixed-citation></ref><ref id="bibr46-19322968251353811"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KM</given-names></name><name name-style="western"><surname>Shin</surname><given-names>JH.</given-names></name></person-group><article-title>Usefulness of continuous glucose monitoring of blood glucose control in patients with diabetes undergoing hemodialysis: a pilot study</article-title>. <source>Front Med (Lausanne)</source>. <year>2023</year>;<volume>10</volume>:<fpage>1145470</fpage>.<pub-id pub-id-type="pmid">37089609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2023.1145470</pub-id><pub-id pub-id-type="pmcid">PMC10117913</pub-id></mixed-citation></ref><ref id="bibr47-19322968251353811"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S-Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YC</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>IC</given-names></name></person-group>, <etal>et al</etal>. <article-title>Glycosylated hemoglobin and albumin-corrected fructosamine are good indicators for glycemic control in peritoneal dialysis patients</article-title>. <source>PLoS ONE</source>. <year>2013</year>;<volume>8</volume>(<issue>3</issue>):e57762.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0057762</pub-id><pub-id pub-id-type="pmcid">PMC3587617</pub-id><pub-id pub-id-type="pmid">23469230</pub-id></mixed-citation></ref><ref id="bibr48-19322968251353811"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>J</given-names></name><name name-style="western"><surname>Ng</surname><given-names>JKC</given-names></name><name name-style="western"><surname>Chan</surname><given-names>JCN</given-names></name><name name-style="western"><surname>Chow</surname><given-names>E.</given-names></name></person-group><article-title>Use of continuous glucose monitoring in the assessment and management of patients with diabetes and chronic kidney disease</article-title>. <source>Front Endocrinol (Lausanne)</source>. <year>2022</year>;<volume>13</volume>:<fpage>869899</fpage>.<pub-id pub-id-type="pmid">35528010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2022.869899</pub-id><pub-id pub-id-type="pmcid">PMC9074296</pub-id></mixed-citation></ref><ref id="bibr49-19322968251353811"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mambelli</surname><given-names>E</given-names></name><name name-style="western"><surname>Cristino</surname><given-names>S</given-names></name><name name-style="western"><surname>Mosconi</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>. <article-title>Flash glucose monitoring to assess glycemic control and variability in hemodialysis patients: the GIOTTO study</article-title>. <source>Front Med (Lausanne)</source>. <year>2021</year>;<volume>8</volume>:<fpage>617891</fpage>.<pub-id pub-id-type="pmid">34395456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2021.617891</pub-id><pub-id pub-id-type="pmcid">PMC8360859</pub-id></mixed-citation></ref><ref id="bibr50-19322968251353811"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marshall</surname><given-names>J</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>P</given-names></name><name name-style="western"><surname>Scott</surname><given-names>A</given-names></name><name name-style="western"><surname>Fluck</surname><given-names>RJ</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>CW.</given-names></name></person-group><article-title>Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS)</article-title>. <source>Kidney Int</source>. <year>2003</year>;<volume>64</volume>(<issue>4</issue>):<fpage>1480</fpage>-<lpage>1486</lpage>.<pub-id pub-id-type="pmid">12969169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1523-1755.2003.00209.x</pub-id></mixed-citation></ref><ref id="bibr51-19322968251353811"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matoba</surname><given-names>K</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>A</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>N</given-names></name><name name-style="western"><surname>Moriguchi</surname><given-names>I</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>N</given-names></name><name name-style="western"><surname>Shichiri</surname><given-names>M.</given-names></name></person-group><article-title>Comparison of accuracy between flash glucose monitoring and continuous glucose monitoring in patients with type 2 diabetes mellitus undergoing hemodialysis</article-title>. <source>J Diabetes Complications</source>. <year>2020</year>;<volume>34</volume>(<issue>11</issue>):<fpage>107680</fpage>.<pub-id pub-id-type="pmid">32736927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdiacomp.2020.107680</pub-id></mixed-citation></ref><ref id="bibr52-19322968251353811"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayeda</surname><given-names>L</given-names></name><name name-style="western"><surname>Galindo</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Navarrete</surname><given-names>JE</given-names></name></person-group>, <etal>et al</etal>. <article-title>Glycemia assessed by continuous glucose monitoring among patients on dialysis: FR-PO468</article-title>. <source>J Am Soc Nephrol</source>. <year>2024</year>;<volume>35</volume>(<issue>10S</issue>):f1mg7svy.</mixed-citation></ref><ref id="bibr53-19322968251353811"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer</surname><given-names>L</given-names></name><name name-style="western"><surname>Chantrel</surname><given-names>F</given-names></name><name name-style="western"><surname>Imhoff</surname><given-names>O</given-names></name></person-group>, <etal>et al</etal>. <article-title>Glycated albumin and continuous glucose monitoring to replace glycated haemoglobin in patients with diabetes treated with haemodialysis</article-title>. <source>Diabet Med</source>. <year>2013</year>;<volume>30</volume>(<issue>11</issue>):<fpage>1388</fpage>-<lpage>1389</lpage>.<pub-id pub-id-type="pmid">23909880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dme.12294</pub-id></mixed-citation></ref><ref id="bibr54-19322968251353811"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirani</surname><given-names>M</given-names></name><name name-style="western"><surname>Berra</surname><given-names>C</given-names></name><name name-style="western"><surname>Finazzi</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. <article-title>Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis</article-title>. <source>Diabetes Technol Ther</source>. <year>2010</year>;<volume>12</volume>(<issue>10</issue>):<fpage>749</fpage>-<lpage>753</lpage>.<pub-id pub-id-type="pmid">20809678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/dia.2010.0052</pub-id></mixed-citation></ref><ref id="bibr55-19322968251353811"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mori</surname><given-names>T</given-names></name><name name-style="western"><surname>Chida</surname><given-names>M</given-names></name><name name-style="western"><surname>Oba</surname><given-names>I</given-names></name></person-group>, <etal>et al</etal>. <article-title>Diurnal variations of blood glucose by continuous blood glucose monitoring in peritoneal dialysis patients with diabetes</article-title>. <source>Adv Perit Dial</source>. <year>2014</year>;<volume>30</volume>:<fpage>54</fpage>-<lpage>59</lpage>.<pub-id pub-id-type="pmid">25338422</pub-id></mixed-citation></ref><ref id="bibr56-19322968251353811"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mori</surname><given-names>K</given-names></name><name name-style="western"><surname>Emoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Abe</surname><given-names>M</given-names></name><name name-style="western"><surname>Inaba</surname><given-names>M.</given-names></name></person-group><article-title>Visualization of blood glucose fluctuations using continuous glucose monitoring in patients undergoing hemodialysis</article-title>. <source>J Diabetes Sci Technol</source>. <year>2019</year>;<volume>13</volume>(<issue>2</issue>):<fpage>413</fpage>-<lpage>414</lpage>.<pub-id pub-id-type="pmid">30580579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1932296818818429</pub-id><pub-id pub-id-type="pmcid">PMC6399784</pub-id></mixed-citation></ref><ref id="bibr57-19322968251353811"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munch</surname><given-names>M</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>L</given-names></name><name name-style="western"><surname>Hannedouche</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>. <article-title>Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: the VILDDIAL study, a randomized, multicentre, prospective study</article-title>. <source>Diabetes Obes Metab</source>. <year>2020</year>;<volume>22</volume>(<issue>6</issue>):<fpage>978</fpage>-<lpage>987</lpage>.<pub-id pub-id-type="pmid">32048396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.13988</pub-id></mixed-citation></ref><ref id="bibr58-19322968251353811"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narasaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Park</surname><given-names>E</given-names></name><name name-style="western"><surname>You</surname><given-names>AS</given-names></name></person-group>, <etal>et al</etal>. <article-title>Continuous glucose monitoring in an end-stage renal disease patient with diabetes receiving hemodialysis</article-title>. <source>Semin Dial</source>. <year>2021</year>;<volume>34</volume>(<issue>5</issue>):<fpage>388</fpage>-<lpage>393</lpage>.<pub-id pub-id-type="pmid">34378258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/sdi.13009</pub-id></mixed-citation></ref><ref id="bibr59-19322968251353811"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>JKC</given-names></name><name name-style="western"><surname>Ling</surname><given-names>J</given-names></name><name name-style="western"><surname>Luk</surname><given-names>AOY</given-names></name></person-group>, <etal>et al</etal>. <article-title>Evaluation of a fourth-generation subcutaneous real-time continuous glucose monitor (CGM) in individuals with diabetes on peritoneal dialysis</article-title>. <source>Diabetes Care</source>. <year>2023</year>;<volume>46</volume>(<issue>6</issue>):<fpage>1191</fpage>-<lpage>1195</lpage>.<pub-id pub-id-type="pmid">37043824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc22-2348</pub-id><pub-id pub-id-type="pmcid">PMC10234746</pub-id></mixed-citation></ref><ref id="bibr60-19322968251353811"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oei</surname><given-names>E</given-names></name><name name-style="western"><surname>Samad</surname><given-names>N</given-names></name><name name-style="western"><surname>Visser</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <article-title>Use of continuous glucose monitoring in patients with diabetes on peritoneal dialysis: poor correlation with HbA1c and high incidence of hypoglycaemia</article-title>. <source>Diabet Med</source>. <year>2016</year>;<volume>33</volume>(<issue>9</issue>):e17-e20.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dme.12988</pub-id><pub-id pub-id-type="pmid">26470840</pub-id></mixed-citation></ref><ref id="bibr61-19322968251353811"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okada</surname><given-names>E</given-names></name><name name-style="western"><surname>Oishi</surname><given-names>D</given-names></name><name name-style="western"><surname>Sakurada</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>. <article-title>A comparison study of glucose fluctuation during automated peritoneal dialysis and continuous ambulatory peritoneal dialysis</article-title>. <source>Adv Perit Dial</source>. <year>2015</year>;<volume>31</volume>:<fpage>34</fpage>-<lpage>37</lpage>.<pub-id pub-id-type="pmid">26714386</pub-id></mixed-citation></ref><ref id="bibr62-19322968251353811"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osonoi</surname><given-names>T</given-names></name><name name-style="western"><surname>Saito</surname><given-names>M</given-names></name><name name-style="western"><surname>Tamasawa</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <article-title>Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study</article-title>. <source>PLoS ONE</source>. <year>2014</year>;<volume>9</volume>(<issue>12</issue>):e113468.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0113468</pub-id><pub-id pub-id-type="pmcid">PMC4272272</pub-id><pub-id pub-id-type="pmid">25526642</pub-id></mixed-citation></ref><ref id="bibr63-19322968251353811"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Popa</surname><given-names>S</given-names></name><name name-style="western"><surname>V&#259;duva</surname><given-names>C</given-names></name><name name-style="western"><surname>Mota</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Peritoneal dialysis&#8212;risk factor for glycemic variability assessed by continuous glucose monitoring system</article-title>. <source>Rom J Diabetes Nutr Metab Dis</source>. <year>2014</year>;<volume>21</volume>(<issue>1</issue>):<fpage>47</fpage>-<lpage>54</lpage>.</mixed-citation></ref><ref id="bibr64-19322968251353811"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qayyum</surname><given-names>A</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>TA</given-names></name><name name-style="western"><surname>Oei</surname><given-names>EL</given-names></name></person-group>, <etal>et al</etal>. <article-title>Use of continuous glucose monitoring in patients with diabetes mellitus on peritoneal dialysis: correlation with glycated hemoglobin and detection of high incidence of unaware hypoglycemia</article-title>. <source>Blood Purif</source>. <year>2016</year>;<volume>41</volume>(<issue>1-3</issue>):<fpage>18</fpage>-<lpage>24</lpage>.<pub-id pub-id-type="pmid">26960210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000439242</pub-id></mixed-citation></ref><ref id="bibr65-19322968251353811"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramos</surname><given-names>C</given-names></name><name name-style="western"><surname>Proen&#231;a de Moraes</surname><given-names>T</given-names></name><name name-style="western"><surname>Bucharles</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. <article-title>WCN24-2063 glycemic variability in patients with type 2 diabetes and dialytic chronic renal failure using different types of basal insulins</article-title>. <source>Kidney Int Rep</source>. <year>2024</year>;<volume>9</volume>(<issue>4 suppl</issue>):S232.</mixed-citation></ref><ref id="bibr66-19322968251353811"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riveline</surname><given-names>J-P</given-names></name><name name-style="western"><surname>Teynie</surname><given-names>J</given-names></name><name name-style="western"><surname>Belmouaz</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. <article-title>Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system</article-title>. <source>Nephrol Dial Transplant</source>. <year>2009</year>;<volume>24</volume>(<issue>9</issue>):<fpage>2866</fpage>.<pub-id pub-id-type="pmid">19389864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfp181</pub-id></mixed-citation></ref><ref id="bibr67-19322968251353811"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>A</given-names></name><name name-style="western"><surname>Montefusco</surname><given-names>L</given-names></name><name name-style="western"><surname>Pastore</surname><given-names>I</given-names></name></person-group>, <etal>et al</etal>. <article-title>One year of hybrid closed loop on peritoneal dialysis: a case report</article-title>. <source>Acta Diabetol</source>. <year>2022</year>;<volume>59</volume>(<issue>7</issue>):<fpage>985</fpage>-<lpage>988</lpage>.<pub-id pub-id-type="pmid">35353250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00592-022-01880-5</pub-id><pub-id pub-id-type="pmcid">PMC9156466</pub-id></mixed-citation></ref><ref id="bibr68-19322968251353811"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savu</surname><given-names>O</given-names></name><name name-style="western"><surname>Elian</surname><given-names>V</given-names></name><name name-style="western"><surname>Steriade</surname><given-names>O</given-names></name></person-group>, <etal>et al</etal>. <article-title>The impact of basal insulin analogues on glucose variability in patients with type 2 diabetes undergoing renal replacement therapy for end-stage renal disease</article-title>. <source>Int Urol Nephrol</source>. <year>2016</year>;<volume>48</volume>(<issue>2</issue>):<fpage>265</fpage>-<lpage>270</lpage>.<pub-id pub-id-type="pmid">26725077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11255-015-1175-x</pub-id></mixed-citation></ref><ref id="bibr69-19322968251353811"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwing</surname><given-names>WD</given-names></name><name name-style="western"><surname>Erhard</surname><given-names>P</given-names></name><name name-style="western"><surname>Newman</surname><given-names>LN</given-names></name></person-group>, <etal>et al</etal>. <article-title>Assessing 24-hour blood glucose patterns in diabetic patients treated by peritoneal dialysis</article-title>. <source>Adv Perit Dial</source>. <year>2004</year>;<volume>20</volume>:<fpage>213</fpage>-<lpage>216</lpage>.<pub-id pub-id-type="pmid">15384829</pub-id></mixed-citation></ref><ref id="bibr70-19322968251353811"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skubala</surname><given-names>A</given-names></name><name name-style="western"><surname>Zywiec</surname><given-names>J</given-names></name><name name-style="western"><surname>Ze&#322;obowska</surname><given-names>K</given-names></name><name name-style="western"><surname>Gumprecht</surname><given-names>J</given-names></name><name name-style="western"><surname>Grzeszczak</surname><given-names>W.</given-names></name></person-group><article-title>Continuous glucose monitoring system in 72-hour glucose profile assessment in patients with end-stage renal disease on maintenance continuous ambulatory peritoneal dialysis</article-title>. <source>Med Sci Monit</source>. <year>2010</year>;<volume>16</volume>(<issue>2</issue>):CR75-CR83.<pub-id pub-id-type="pmid">20110918</pub-id></mixed-citation></ref><ref id="bibr71-19322968251353811"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toyoda</surname><given-names>M</given-names></name><name name-style="western"><surname>Murata</surname><given-names>T</given-names></name><name name-style="western"><surname>Saito</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>. <article-title>Assessment of the accuracy of an intermittent-scanning continuous glucose monitoring device in patients with type 2 diabetes mellitus undergoing hemodialysis (AIDT2H) study</article-title>. <source>Ther Apher Dial</source>. <year>2021</year>;<volume>25</volume>(<issue>5</issue>):<fpage>586</fpage>-<lpage>594</lpage>.<pub-id pub-id-type="pmid">33403763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1744-9987.13618</pub-id><pub-id pub-id-type="pmcid">PMC8495855</pub-id></mixed-citation></ref><ref id="bibr72-19322968251353811"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ugamura</surname><given-names>D</given-names></name><name name-style="western"><surname>Hosojima</surname><given-names>M</given-names></name><name name-style="western"><surname>Kabasawa</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>. <article-title>An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis</article-title>. <source>Ren Replace Ther</source>. <year>2022</year>;<volume>8</volume>(<issue>1</issue>):<fpage>26</fpage>.</mixed-citation></ref><ref id="bibr73-19322968251353811"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ushigome</surname><given-names>E</given-names></name><name name-style="western"><surname>Matsusaki</surname><given-names>S</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>N</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>N</given-names></name><name name-style="western"><surname>Fukui</surname><given-names>M.</given-names></name></person-group><article-title>Critical discrepancy in blood glucose control levels evaluated by glycated albumin and estimated hemoglobin A1c levels determined from a flash continuous glucose monitoring system in patients with type 2 diabetes on hemodialysis</article-title>. <source>J Diabetes Investig</source>. <year>2020</year>;<volume>11</volume>(<issue>6</issue>):<fpage>1570</fpage>-<lpage>1574</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdi.13286</pub-id><pub-id pub-id-type="pmcid">PMC7610128</pub-id><pub-id pub-id-type="pmid">32356596</pub-id></mixed-citation></ref><ref id="bibr74-19322968251353811"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villard</surname><given-names>O</given-names></name><name name-style="western"><surname>Breton</surname><given-names>MD</given-names></name><name name-style="western"><surname>Rao</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. <article-title>Accuracy of a factory-calibrated continuous glucose monitor in individuals with diabetes on hemodialysis</article-title>. <source>Diabetes Care</source>. <year>2022</year>;<volume>45</volume>(<issue>7</issue>):<fpage>1666</fpage>-<lpage>1669</lpage>.<pub-id pub-id-type="pmid">35485908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc22-0073</pub-id></mixed-citation></ref><ref id="bibr75-19322968251353811"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wada</surname><given-names>N</given-names></name><name name-style="western"><surname>Mori</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>. <article-title>Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: evaluation by continuous glucose monitoring</article-title>. <source>J Diabetes Complications</source>. <year>2015</year>;<volume>29</volume>(<issue>8</issue>):<fpage>1310</fpage>-<lpage>1313</lpage>.<pub-id pub-id-type="pmid">26298521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdiacomp.2015.07.002</pub-id></mixed-citation></ref><ref id="bibr76-19322968251353811"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Kyi</surname><given-names>M</given-names></name><name name-style="western"><surname>Krishnamoorthi</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal>. <article-title>Accuracy of continuous glucose monitoring in people with type 1 diabetes receiving hemodialysis in hospital</article-title>. <source>J Diabetes Sci Technol</source>. <year>2025</year>;<volume>19</volume>(<issue>3</issue>):<fpage>859</fpage>-<lpage>861</lpage>.<pub-id pub-id-type="pmid">39950377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/19322968251318758</pub-id><pub-id pub-id-type="pmcid">PMC11830158</pub-id></mixed-citation></ref><ref id="bibr77-19322968251353811"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>MR</given-names></name><name name-style="western"><surname>Diebold</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Accuracy of flash glucose monitoring in hemodialysis patients with and without diabetes mellitus</article-title>. <source>Exp Clin Endocrinol Diabetes</source>. <year>2023</year>;<volume>131</volume>(<issue>3</issue>):<fpage>132</fpage>-<lpage>141</lpage>.<pub-id pub-id-type="pmid">36377191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-1978-0226</pub-id><pub-id pub-id-type="pmcid">PMC9998185</pub-id></mixed-citation></ref><ref id="bibr78-19322968251353811"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>J</given-names></name><name name-style="western"><surname>Gilchrist</surname><given-names>M</given-names></name><name name-style="western"><surname>Strain</surname><given-names>WD</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>D</given-names></name><name name-style="western"><surname>Shore</surname><given-names>A.</given-names></name></person-group><article-title>24-h glycaemic profiles in peritoneal dialysis patients and non-dialysis controls with advanced kidney disease</article-title>. <source>Perit Dial Int</source>. <year>2022</year>;<volume>42</volume>(<issue>5</issue>):<fpage>497</fpage>-<lpage>504</lpage>.<pub-id pub-id-type="pmid">34579595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/08968608211047787</pub-id></mixed-citation></ref><ref id="bibr79-19322968251353811"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yajima</surname><given-names>T</given-names></name><name name-style="western"><surname>Yajima</surname><given-names>K</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>M</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>K.</given-names></name></person-group><article-title>Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2016</year>;<volume>122</volume>:<fpage>78</fpage>-<lpage>83</lpage>.<pub-id pub-id-type="pmid">27810689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2016.10.016</pub-id></mixed-citation></ref><ref id="bibr80-19322968251353811"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yajima</surname><given-names>T</given-names></name><name name-style="western"><surname>Yajima</surname><given-names>K</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>M</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>K.</given-names></name></person-group><article-title>Serum albumin-adjusted glycated albumin as a better indicator of glycemic control in type 2 diabetes mellitus patients with short duration of hemodialysis</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2017</year>;<volume>130</volume>:<fpage>148</fpage>-<lpage>153</lpage>.<pub-id pub-id-type="pmid">28641154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2017.05.020</pub-id></mixed-citation></ref><ref id="bibr81-19322968251353811"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yajima</surname><given-names>T</given-names></name><name name-style="western"><surname>Yajima</surname><given-names>K</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>M</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>K.</given-names></name></person-group><article-title>Improved glycemic control with once-weekly dulaglutide in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring</article-title>. <source>J Diabetes Complications</source>. <year>2018</year>;<volume>32</volume>(<issue>3</issue>):<fpage>310</fpage>-<lpage>315</lpage>.<pub-id pub-id-type="pmid">29366733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdiacomp.2017.12.005</pub-id></mixed-citation></ref><ref id="bibr82-19322968251353811"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yajima</surname><given-names>T</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>K.</given-names></name></person-group><article-title>Comparison of interstitial fluid glucose levels obtained by continuous glucose monitoring and flash glucose monitoring in patients with type 2 diabetes mellitus undergoing hemodialysis</article-title>. <source>J Diabetes Sci Technol</source>. <year>2020</year>;<volume>14</volume>(<issue>6</issue>):<fpage>1088</fpage>-<lpage>1094</lpage>.<pub-id pub-id-type="pmid">31625413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1932296819882690</pub-id><pub-id pub-id-type="pmcid">PMC7645125</pub-id></mixed-citation></ref><ref id="bibr83-19322968251353811"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wadwa</surname><given-names>RP</given-names></name><name name-style="western"><surname>Laffel</surname><given-names>LM</given-names></name><name name-style="western"><surname>Shah</surname><given-names>VN</given-names></name><name name-style="western"><surname>Garg</surname><given-names>SK.</given-names></name></person-group><article-title>Accuracy of a factory-calibrated, real-time continuous glucose monitoring system during 10 days of use in youth and adults with diabetes</article-title>. <source>Diabetes Technol Ther</source>. <year>2018</year>;<volume>20</volume>(<issue>6</issue>):<fpage>395</fpage>-<lpage>402</lpage>.<pub-id pub-id-type="pmid">29901421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/dia.2018.0150</pub-id><pub-id pub-id-type="pmcid">PMC6110124</pub-id></mixed-citation></ref><ref id="bibr84-19322968251353811"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bailey</surname><given-names>TS</given-names></name><name name-style="western"><surname>Chang</surname><given-names>A</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>M.</given-names></name></person-group><article-title>Clinical accuracy of a continuous glucose monitoring system with an advanced algorithm</article-title>. <source>J Diabetes Sci Technol</source>. <year>2015</year>;<volume>9</volume>(<issue>2</issue>):<fpage>209</fpage>-<lpage>214</lpage>.<pub-id pub-id-type="pmid">25370149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1932296814559746</pub-id><pub-id pub-id-type="pmcid">PMC4604574</pub-id></mixed-citation></ref><ref id="bibr85-19322968251353811"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aberer</surname><given-names>F</given-names></name><name name-style="western"><surname>Hajnsek</surname><given-names>M</given-names></name><name name-style="western"><surname>Rumpler</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Evaluation of subcutaneous glucose monitoring systems under routine environmental conditions in patients with type 1 diabetes</article-title>. <source>Diabetes Obes Metab</source>. <year>2017</year>;<volume>19</volume>(<issue>7</issue>):<fpage>1051</fpage>-<lpage>1055</lpage>.<pub-id pub-id-type="pmid">28205324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.12907</pub-id></mixed-citation></ref><ref id="bibr86-19322968251353811"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andelin</surname><given-names>M</given-names></name><name name-style="western"><surname>Kropff</surname><given-names>J</given-names></name><name name-style="western"><surname>Matuleviciene</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal>. <article-title>Assessing the accuracy of continuous glucose monitoring (CGM) calibrated with capillary values using capillary or venous glucose levels as a reference</article-title>. <source>J Diabetes Sci Technol</source>. <year>2016</year>;<volume>10</volume>(<issue>4</issue>):<fpage>876</fpage>-<lpage>884</lpage>.<pub-id pub-id-type="pmid">26810924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1932296815626724</pub-id><pub-id pub-id-type="pmcid">PMC4928217</pub-id></mixed-citation></ref><ref id="bibr87-19322968251353811"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keenan</surname><given-names>DB</given-names></name><name name-style="western"><surname>Mastrototaro</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Zisser</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>. <article-title>Accuracy of the Enlite 6-day glucose sensor with guardian and Veo calibration algorithms</article-title>. <source>Diabetes Technol Ther</source>. <year>2012</year>;<volume>14</volume>(<issue>3</issue>):<fpage>225</fpage>-<lpage>231</lpage>.<pub-id pub-id-type="pmid">22145851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/dia.2011.0199</pub-id></mixed-citation></ref><ref id="bibr88-19322968251353811"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christiansen</surname><given-names>MP</given-names></name><name name-style="western"><surname>Garg</surname><given-names>SK</given-names></name><name name-style="western"><surname>Brazg</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>. <article-title>Accuracy of a fourth-generation subcutaneous continuous glucose sensor</article-title>. <source>Diabetes Technol Ther</source>. <year>2017</year>;<volume>19</volume>(<issue>8</issue>):<fpage>446</fpage>-<lpage>456</lpage>.<pub-id pub-id-type="pmid">28700272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/dia.2017.0087</pub-id><pub-id pub-id-type="pmcid">PMC5567873</pub-id></mixed-citation></ref><ref id="bibr89-19322968251353811"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhee</surname><given-names>CM</given-names></name><name name-style="western"><surname>Gianchandani</surname><given-names>RY</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>. <article-title>Consensus report on the use of continuous glucose monitoring in chronic kidney disease and diabetes</article-title>. <source>J Diabetes Sci Technol</source>. <year>2025</year>;<volume>19</volume>:<fpage>217</fpage>-<lpage>245</lpage>.<pub-id pub-id-type="pmid">39611379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/19322968241292041</pub-id><pub-id pub-id-type="pmcid">PMC11607725</pub-id></mixed-citation></ref><ref id="bibr90-19322968251353811"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heinemann</surname><given-names>L</given-names></name><name name-style="western"><surname>Schoemaker</surname><given-names>M</given-names></name><name name-style="western"><surname>Schmelzeisen-Redecker</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>. <article-title>Benefits and limitations of MARD as a performance parameter for continuous glucose monitoring in the interstitial space</article-title>. <source>J Diabetes Sci Technol</source>. <year>2020</year>;<volume>14</volume>(<issue>1</issue>):<fpage>135</fpage>-<lpage>150</lpage>.<pub-id pub-id-type="pmid">31216870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1932296819855670</pub-id><pub-id pub-id-type="pmcid">PMC7189145</pub-id></mixed-citation></ref><ref id="bibr91-19322968251353811"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pleus</surname><given-names>S</given-names></name><name name-style="western"><surname>Schoemaker</surname><given-names>M</given-names></name><name name-style="western"><surname>Schoemaker</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Rate-of-change dependence of the performance of two CGM systems during induced glucose swings</article-title>. <source>J Diabetes Sci Technol</source>. <year>2015</year>;<volume>9</volume>(<issue>4</issue>):<fpage>801</fpage>-<lpage>807</lpage>.<pub-id pub-id-type="pmid">25852074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1932296815578716</pub-id><pub-id pub-id-type="pmcid">PMC4525645</pub-id></mixed-citation></ref><ref id="bibr92-19322968251353811"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desouza</surname><given-names>CV</given-names></name><name name-style="western"><surname>Rosenstock</surname><given-names>J</given-names></name><name name-style="western"><surname>Kohzuma</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>. <article-title>Glycated albumin correlates with time-in-range better than HbA1c or fructosamine</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2023</year>;<volume>108</volume>(<issue>11</issue>):e1193-e1198.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgad298</pub-id><pub-id pub-id-type="pmcid">PMC10583977</pub-id><pub-id pub-id-type="pmid">37259605</pub-id></mixed-citation></ref><ref id="bibr93-19322968251353811"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodbard</surname><given-names>D.</given-names></name></person-group><article-title>Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes</article-title>. <source>Diabetes Technol Ther</source>. <year>2017</year>;<volume>19</volume>(<issue>S3</issue>):S25-S37.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/dia.2017.0035</pub-id><pub-id pub-id-type="pmcid">PMC5467105</pub-id><pub-id pub-id-type="pmid">28585879</pub-id></mixed-citation></ref><ref id="bibr94-19322968251353811"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jancev</surname><given-names>M</given-names></name><name name-style="western"><surname>Vissers</surname><given-names>TACM</given-names></name><name name-style="western"><surname>Visseren</surname><given-names>FLJ</given-names></name></person-group>, <etal>et al</etal>. <article-title>Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis</article-title>. <source>Diabetologia</source>. <year>2024</year>;<volume>67</volume>(<issue>5</issue>):<fpage>798</fpage>-<lpage>810</lpage>.<pub-id pub-id-type="pmid">38363342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-024-06107-6</pub-id><pub-id pub-id-type="pmcid">PMC10954850</pub-id></mixed-citation></ref><ref id="bibr95-19322968251353811"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crabtree</surname><given-names>TSJ</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>TP</given-names></name><name name-style="western"><surname>Yap</surname><given-names>YW</given-names></name></person-group>, <etal>et al</etal>. <article-title>Hybrid closed-loop therapy in adults with type 1 diabetes and above-target HbA1c: a real-world observational study</article-title>. <source>Diabetes Care</source>. <year>2023</year>;<volume>46</volume>(<issue>10</issue>):<fpage>1831</fpage>-<lpage>1838</lpage>.<pub-id pub-id-type="pmid">37566697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc23-0635</pub-id><pub-id pub-id-type="pmcid">PMC10516256</pub-id></mixed-citation></ref><ref id="bibr96-19322968251353811"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kudva</surname><given-names>YC</given-names></name><name name-style="western"><surname>Raghinaru</surname><given-names>D</given-names></name><name name-style="western"><surname>Lum</surname><given-names>JW</given-names></name></person-group>, <etal>et al</etal>. <article-title>A randomized trial of automated insulin delivery in type 2 diabetes</article-title>. <source>N Engl J Med</source>. <year>2025</year>;<volume>392</volume>(<issue>18</issue>):<fpage>1801</fpage>-<lpage>1812</lpage>.<pub-id pub-id-type="pmid">40105270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2415948</pub-id></mixed-citation></ref><ref id="bibr97-19322968251353811"><label>97</label><mixed-citation publication-type="journal"><collab>Kidney Disease: Improving Global Outcomes (KDIGO)</collab>. <article-title>Clinical practice guideline for diabetes management in chronic kidney disease</article-title>. <source>Kidney Int</source>. <year>2022</year>;<volume>102</volume>:S1-S127.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2022.06.008</pub-id><pub-id pub-id-type="pmid">36272764</pub-id></mixed-citation></ref><ref id="bibr98-19322968251353811"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laursen</surname><given-names>SH</given-names></name><name name-style="western"><surname>De Salvo</surname><given-names>C</given-names></name><name name-style="western"><surname>Lunati</surname><given-names>ME</given-names></name></person-group>, <etal>et al</etal>. <article-title>A continuous glucose monitoring device as a valuable tool for supporting diabetes care in haemodialysis patients: a qualitative interview study</article-title>. <source>Nord J Nurs Res</source>. <year>2025</year>;<volume>45</volume>:20571585251331199.</mixed-citation></ref><ref id="bibr99-19322968251353811"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joseph</surname><given-names>K</given-names></name><name name-style="western"><surname>Avari</surname><given-names>P</given-names></name><name name-style="western"><surname>Goldet</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>. <article-title>The impact of diabetes specialist nurses&#8217; in-reach service on people with diabetes on haemodialysis: a pilot study &#8220;education to protect tomorrow.&#8221;</article-title><source>Diabet Med</source>. <year>2024</year>;<volume>41</volume>(<issue>7</issue>):e15306.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dme.15306</pub-id><pub-id pub-id-type="pmid">38343111</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>